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Structure-activity relationships of the h igh-affin ity  g lu tam ate transporters 
in synaptosom es.
Research advisor: R ichard J. Bridges, Ph.D.
W ithin the  m am m alian  central nervous system , the efficient rem oval of 
the n eu ro tran sm itte r L-glutam ate from  the extracellular space by 
excitatory am ino acid transporters (EAATs) has been postu lated  to 
contribute to signal term ination , the recycling of transm itter, and the  
m aintenance of L-glutam ate a t concentrations below  those w hich are 
excitotoxic. In  the p resen t study, several no v e l series of L-glutam ate 
analogues, includ ing  the 2,3-pyrrolidine dicarboxylates and  3,4- 
m ethanopyrro lid ine  dicarboxylates, w ere investigated  for their activity as 
inhibitors of the high-affinity g lutam ate tran sp o rt system  presen t in rat 
forebrain synaptosom es. Further, these novel analogues, as well as a 
library of previously  identified uptake inhibitors, w ere used  to address two 
key issues: the differentiation of substrates from  non transportab le
inhibitors and  the com parison of the pharm acological profile of 
synaptosom al up take  w ith  those of the in d iv id u a l EAAT clones. It was 
dem onstrated  that the  process of transporter-m ed ia ted  heteroexchange 
could be exploited in  synaptosom es in  o rder to rapid ly  d istingu ish  
transportable from  nontransportab le  inhibitors. U sing this approach, we 
identified 2,4-m ethanopyrrolidine-2,4-dicarboxylate, cz's-1-
am inocyclobutane-l,3-dicarboxylate, and  L-fnm s-2,4-pyrrolidine
dicarboxylate as substrates for the synaptosom al g lu tam ate  up take system. 
In contrast, L-zm£z-endo-3,4-methanopyrrolidine dicarboxylate, L-trans-2,3- 
pyrrolid ine dicarboxylate and d ihydrokainate  p ro v ed  to be com petitive 
inhibitors of g lu tam ate  transport that exhibited little or no activity as 
substrates. W hen these same com pounds w ere electrophysiologically 
characterized for substrate  activity in  X enopus  oocytes expressing the 
hum an  transporter clones EAAT1, EAAT2 or EAAT3, it w as found that 
the pharm acological profile of the synaptosom al system  exhibited the 
greatest sim ilarity  w ith  the EAAT2 subtype, a  tran sp o rte r believed to be 
expressed p rim arily  on  glial cells. In  the final po rtion  of the study, we 
exam ined the efflux of excitatory am ino a d d  in  response to a m etabolic 
insult (5 m M  KCN and  1 mM iodoacetate). Exposure of synaptosom es 
containing [3H ]-D -aspartate to the m etabolic inhibitors increased the efflux 
of the radiolabeled substra te  to over 200% of contro l values. The indusion  
of L-frzms-2,3-pyrrolidine dicarboxylate and  d ihydrokainate , bo th  identified 
as non transportab le  uptake inhibitors, significantly a ttenuated  the  
metabolic inhibitor-induced efflux. These findings add  fu rther strength to 
the m odel of CNS in jury-induced efflux of L-glutam ate th rough  its high- 
affinity transporters and  identify a novel strategy to  a ttenuate this process.
l i
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C hapter 1: B ackground an d  In troduction
N early  th ree  decades passed betw een the  orig inal experim ents 
dem onstrating  th a t L-glutam ate could cause neu rona l excitation (Curtis e t 
al., 1959) and  the  even tual acceptance of this a -am ino  acid as the prim ary  
excitatory n eu ro tran sm itte r  in  the m am m alian  central nervous system 
(CNS). The reluctance to acknowledge L-glutam ate as a tran sm itte r 
candidate w as due , a t least in  part, to its om nipresence in  virtually  all 
biological processes as w ell as its diverse roles as a bu ild ing  block in the  
synthesis of pep tides and  proteins, and  as a central m olecule in  
in term ediary  m etabolism . L-Glutam ate is now  recognized as one of the  
class o f am ino acid  neurotransm itters tha t accounts for the m ajority of all 
transm ission  w ith in  the m am m alian  CNS. As the p rim ary  excitatory 
am ino a d d  (EAA) transm itter, L-glutam ate has been  found  to participate 
in standard  fast synaptic transm ission  as well as the  h igher order signal 
processing requ ired  for developm ent, p lastid ty , learn ing  and  m em ory (for 
review  see: C otm an et al., 1995).
L-G lutam ate m ediates these functions th rough  the activation of 
m ultip le  EAA receptor classes (Figure 1.1), in d u d in g  the ionotropic (ion  
channel-coupled) and  m etabotropic (second m essenger-coupled) subtypes. 
The ionotropic receptors w ere initially identified and d istinguished  
pharm acologically  by the selective agonists for w hich  they  w ere nam ed, 
i.e., N -m ethyl-D -aspartate  (NMDA), kainic a d d  (KA), and  a-am ino-3- 
hydroxy-5-m ethyl-4-isoxazole propionic a d d  (AMPA). These receptors 
typically gate cu rren ts carried by N a+, fC, and  often tim es Ca2+ ions (for 
review , see: D ingledine et al., 1999). The m etabotropic glutam ate
1
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receptors (mGluRs) w ere originally characterized and nam ed after the  
agonists frans-l-am inocyclopentane-l,3-dicarboxylic acid (trans-ACPD) and  
L-2-am ino-phosphonobutyric a d d  (L-AP4), and  are coupled via guan ine  
nucleotide b ind ing  proteins (G proteins) to either 3'J5'-cyclic adenosine  
m onophosphate  (cAMP) or phosphoinositol (PI) second m essenger 
systems (Conn and  Pin, 1997).
In stark  con trast to the norm al processes m ediated by th is  
neuro transm itter, over-stim ulation  of the EAA receptors by excessive 
levels of L -glutam ate can result in a type of neuronal dam age know n as 
exdtotoxicity (R othm an and Olney, 1987; Choi, 1988; Choi, 1994; R o th m a n  
and Olney, 1995). The first com ponent of this pathology, or the acute 
phase, is in itia ted  by the influx of excessive am ounts of N a+ th ro u g h  
activated EAA receptors. This is then followed by the passive influx of Cl" 
and w ater, and  th u s  consequent cell swelling. The second com ponent is 
thought to be associated w ith  more long term  neurodegeneration  and  
revolves a round  th e  loss of Ca2+ homeostasis. Excess intracellu lar Ca2+, 
m ost likely a resu lt of influx through activated NMD A receptors, as w ell 
as release from  in tracellu lar stores, has been show n to result in  the  
activation proteolytic and lipolytic enzym es, increase in  free radical 
production, apoptosis, and  eventual cellular degeneration (for review, see: 
Choi, 1995). Exdtotoxic neuropathology is though t to be a factor in  a 
num ber of CNS pathologies., including acute CNS injuries such as stroke, 
ischemia, anoxia and  traum a, as well as chronic neu ro  degenera tive  
syndrom es such as am yotrophic lateral sderosis (ALS), H u n tin g to n 's  
disease, and  A lzheim er's  disease (Choi, 1994; R othm an and  Olney, 1995; 
Leigh and  M eldrum , 1996; Arzberger et al., 1997; Olney et al., 1997).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3
The balance betw een  the physiological and  pathological actions of L- 
glutam ate is though t, a t least in  p a rt, to be kep t in  check by the rapid  
rem oval of th is acidic am ino acid from  the synaptic  cleft. W hile a n u m b e r 
of system s have been  identified th a t are capable of transporting  L- 
glutam ate into  cells, the  m ajority  of up take  w ith in  the CNS appears to be 
m ediated by the  h igh-affinity , so d iu m -d ep en d en t excitatory am ino acid 
transporters (EAATs) (for review  see: G egelashvili and Schousboe, 1997; 
Vandenberg, 1998). T ransport of L -glutam ate by  the EAATs is electrogenic 
and is driven  p rim arily  by  the trans-m em brane sod ium  grad ien t generated 
by N a+/K + ATPases (for review  see: Rudnick, 1998). The efficient rem o v a l 
of L-glutam ate from  the  extracellu lar space by these system s has been  
postulated to con tribu te  to signal te rm ina tion , the recycling of the  
transm itter, and  the m ain tenance  of L-glutam ate a t concentrations below  
those w hich are excitotoxic (for rev iew  see: Takahashi et al., 1997).
Several subtypes of so d iu m -d ep en d en t g lu tam ate  transporters h av e  
been isolated and  cloned from  m am m alian  tissue, including  GLAST and  
GLT-1 from  ra t brain , and  EAAC-1 from  rabbit intestine (Kanai and  
Hediger, 1992; Pines et al., 1992; Storck et al., 1992). The h u m a n  
hom ologues of these transporters, EAAT1, EAAT2 and  EAAT3, 
respectively, have  also been iden tified  (A rriza et al., 1994). Studies of 
cellular expression indicate  that EAAT1/GLA ST and  EAAT2/GLT-1 are 
present p rim arily  on  astrocytes, w hereas the EAAT3/EAAC-1 subtype is 
preferentially found  on  neu rons (for review  see: G egelashvili and  
Schousboe, 1998). M ore recent investigations have revealed  tw o 
additional h u m an  subtypes: EAAT4, w hich  is selectively found  in
cerebellar tissue, and  EAAT5, a  re tina l transporte r (Fairm an e t al., 1995;
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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A rriza et al., 1997). C loning o f  the  transporters provided the  m eans w ith  
w hich  to ind iv idua lly  express the proteins in  cell system s, such as 
X enopus  oocytes, and  hence allow ed for the delineation of m ore  precise 
functional characteristics. C u rren t m odeling of EAAT sto ich iom etry  
suggests that L-glutam ate is co-transported w ith  3 sodium  ions and a 
p ro to n  in  exchange for one p o tassiu m  ion (Figure 1.2), and th a t uptake is 
also associated w ith  a  non-therm odynam ically  coupled chloride 
conductance (Zerangue and  K avanaugh, 1996; Levy et al., 1998).
O u r understand ing  of the  pharm acological specificity of these 
transporters, as w ell as their functional roles, has benefited greatly  from  
the developm en t of po ten t a n d  selective inhibitors. C onform ationally  
constrained analogues of L -glutam ate, like those tha t proved invaluable in  
the delineation  of the EAA receptors, have been especially usefu l in th is  
regard  (C ham berlin  et al., 1998). The acyclic structure of L -glutam ate 
allow s for a good deal of fo ld ing  and  rotation of the molecule an d  thus the  
assum ption  of a w ide range of conform ations. As a consequence of their 
restricted  flexibility, the constrained  analogues are capable of m im ick in g  
only a very  lim ited num ber of the  conform ations tha t are a ttainable by L- 
g lu tam ate. N ot only does this allow  for the positions of the functional 
g roups required for b ind ing  to the  system s to be defined, it also decreases 
the num ber of b ind ing  sites the com pound can occupy, thereby increasing  
selectivity. Often these com pounds are designed with the goal of 
em bedd ing  L -glutam ate or L-aspartate (or a portion  thereof) in to  a ring  
system . This strategy led to the  developm ent of uptake inhibitors such as 
L-frans-2,4-pyrrolidine dicarboxylate (L-trans-2,4-PDC), (2S,3S,4R)-2- 
(carboxycydopropyl)glycine (L-CCG-III), czs-l-aminocyclobutane-1,3-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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dicarboxylate (czs-ACBD), and D,L-(3-tfzreo-hydroxyaspartate (D,L-(3-THA) 
(Figure 1.3). Initially used to characterize the pharm acology of g lu tam ate  
uptake in physiological preparations such  as synaptosom es, tissue slices 
and cell cultures, these inhibitors h av e  m ore recently been em ployed in  
expression system s and used to p robe the specificity of the cloned 
transporters (Arriza et al., 1994; Y am ashita et al., 1995; Esslinger et al., 
1998).
Ironically, under som e pathological conditions the sam e high-affinity , 
sod ium -dependen t up take system s th a t norm ally m ain ta in  a  norm oxic  
synaptic environm ent m ay actually participate in the excitotoxic process by 
acting as sites of efflux of L-glutam ate from  intracellu lar com partm en ts 
(Takahashi et al., 1997). N um erous stud ies have suggested tha t m etabolic 
insults w hich  com prom ise cellular energy levels can lead to the  reversed  
action of the transporters and the m ovem en t of L-glutam ate d ow n  its 
concentration gradient into the extracellular space (K auppinen et al., 1988; 
Sanchez-Prieto and Gonzalez, 1988; G em ba et al., 1994; Szatkow ski and 
Attwell, 1994; Longuem are and Sw anson, 1995). This pathw ay, possibly in  
com bination  w ith  alternative  routes o f L-glutam ate efflux (K im elberg et 
al., 1990), could  contribute to the rise in  extracellular glutam ate levels 
observed in  m odels of anoxia and ischem ia (Benveniste et al., 1984; 
Roettiger and  Lipton, 1996).
The w ork  detailed in the presen t study  was conducted essentially in  
three phases. First, several series of novel conform ationally constrained  
glutam ate analogues, including 2,3-pyrrolidine dicarboxylates, 3,4- 
m ethanopyrro lid ine  dicarboxylates and 2 ,4 -m ethanopyrro lid ine 
dicarboxylate, were tested for the ability to inhibit the  h igh-affin ity ,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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sodium -dependent tran spo rt system  present in  forebrain synaptosom es. 
Detailed studies were included  to kinetically characterize the p o ten t 
inhibitors. The second phase of the study  tested the hypothesis th a t 
analogues could be classified e ither as substrate or nonsubstra te  inh ib ito rs 
of the high-affinity transporters. In other w ords, it w as p resum ed  that a 
distinction could be m ade betw een com pounds that com pete  w ith  L- 
glutam ate for the b ind ing  site and are then  transported  (substrate 
inhibitors), and inhibitors that compete for b ind ing  b u t  are n o t 
translocated (nontransportable inhibitors). This was accom plished by 
utilizing the process of transporter-m ediated  heteroexchange, in  w hich a n  
externally applied substrate, such as L-glutam ate, stim ulates the  efflux of 
an  internal substrate, e.g. D -aspartate, that had  been previously  sequestered 
into the synaptosom es. Thus, in lieu of radiolabeling th e  in d iv id u a l 
analogues, transporter-m ediated  heteroexchange could be efficiently 
exploited to evaluate a large num ber of com pounds for substra te  activity. 
The final phase of the study  tested the hypothesis tha t high-affin ity  
glutam ate transporters could  reverse direction du ring  a m etabolic in su lt 
and release am ino acid into the extracellular space. This was 
accom plished by exposing synaptosom es containing radiolabeled D- 
aspartate to a sim plified chem ical m odel of ischem ia/anoxia. T he  
com bination of potassium  cyanide and  iodoacetate w as used  because of its 
ability to effectively inh ib it respiration, deplete ATP levels, and  erode 
synaptosom al m em brane potentials. Exposure of the synaptosom es to th is  
metabolic insult increased the efflux of radiolabeled substrate to  over 200% 
of control values. Inclusion of the nontransportable up take inhibitors L- 
trans- 2,3-pyrrolidine dicarboxylate and d ihydrokainate  significantly
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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a ttenuated  the  m etabolic in h ib ito r-in d u ced  efflux. This finding no t on ly  
provides new  insigh t into th e  tran sp o rt m echanism  b u t also adds fu rth e r  
streng th  to the  m odel o f CNS injury-induced efflux of L -glutam ate 
th rough  the high-affinity  tran sp o rte rs .
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The specific aim s of this project will be  to:
1) Delineate the pharm acophore  of the sod ium -dependen t, h igh-affin ity  
glutam ate tran spo rte r by using a library  of novel, conform ationally  
constrained g lu tam ate  analogues th a t are based on  the py rro lid ine  
dicarboxylate (PDC) structure . This structure-activ ity  data will th en  be 
used to develop a pharm acophore  m odel for the synaptosom al g lu tam ate  
transporter.
2) D eterm ine if the inh ib ito rs identified  in  Specific A im s 1 are substrates 
or non transportab le  inh ib ito rs of the  synaptosom al glutam ate carrier by 
utilizing the process of heteroexchange.
3) Kinetically characterize the efflux of am ino acid neurotransm itters from  
synaptosom es observed during  a m etabolic in jury  and  com pare th is 
process w ith  th a t seen d u rin g  heteroexchange.
4) Q uantify the ability of substrates an d  non transportab le  inhibitors of 
glutam ate up take  to a lter the m etabolic in ju ry -induced  efflux of a m in o  
acid neuro transm itters from  synaptosom es.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 1.1: Excitatory Am ino A d d  Synapse 9
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Figure 1.2: Proposed Stoichiom etry for N a+-D ependent G lutam ate T ransport
K+ 3Na+ H+ Glu"
T0K+ + + To « TcNa3+-«—W  TGNa3+H+ T0Na3+H+Glir
TiNa3+H+Glu
K+ 3Na+ H+ Glu-
A cu rren t m odel for h igh-affin ity , so d iu m  d ep en d en t u p tak e  of L- 
glutam ate (Glu-) suggests th a t 3 sod ium  ions m ust first b in d  to the 
transporter on  the extracellular surface (T0), followed by  the sequential
binding of one proton and  one molecule of L-glutamate. The m ovem ent of 
the transporter to the in tracellu lar surface (Ti) is then  follow ed by  the 
sequential unb ind ing  of L-glutam ate, the proton, and the three sodium  
ions. The transporter then  re tu rns to the extracellular surface w ith  one 
potassium  ion, w hich m ust th en  unb in d  in  order for ano ther cycle of 
transport to begin (Zerangue an d  K avanaugh, 1996).
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C hapter 2: M ethods and  M aterials
The dev elo p m en t of conform ationally  constrained inhibitors of the  
glutam ate transporters, as well as the  testing of p roposed ph a rm aco p h o re  
m odels, is u ltim ately  dependen t u p o n  assessing the  ability of th e  
analogues to  b ind  to the substrate site on  the transport proteins. This has 
typically been  accom plished by quantify ing  the capacity of analogues to 
com petitively inh ib it the uptake of a radiolabeled substrate (e.g., [3H]-L- 
glutam ate or [3H]-D-aspartate) in to  any one of a n u m ber of CNS 
preparations (e.g., b ra in  slices (Balcar an d  Johnston, 1972), p rim ary  cultures 
of neu rons or glia (Garlin et al., 1995), or synaptosom es (Bridges e t al., 
1994). As synaptosom es can be rap id ly  prepared and easily used  to screen 
large num bers of analogues, this p repara tion  has been  w idely  em ployed in  
structure-activ ity  studies (Bridges et al., 1991; Fletcher e t al., 1991; 
N akam ura e t al., 1993).
W hile the  various p reparations of CNS tissue m ay p rov ide  a m o re  
relevant pharm acological overv iew  of transport as it occurs in v iv o , th e  
systems do  suffer from  po ten tia l com plications associated w ith  
heterogeneity. As an  alternative, the recent cloning and  expression of 
distinct g lu tam ate  transporters has allow ed each of the subtypes to be 
selectively characterized. A dvantageously , expression of the in d iv id u a l 
transporters in  oocytes perm its up take  to be quantified bo th  b iochem ically  
and electrophysiologically (Arriza e t al., 1994). M easurem ent of up take- 
induced curren ts prov ides an  approach  to assess the suitability  of 
glutam ate analogues as transporter substrates that is n o t dependen t u p o n  
the availability  of radiolabeled analogues. In  contrast, it  m u st be
12
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rem em bered tha t com petitive  inhibition studies w ith  radiolabeled 
substrates address only w h e th er or not an  analogue b inds to th e  
transporter, n o t if it is also translocated. This lim ita tion  can  be in p a rt 
overcom e in m ore trad itional neurochem ical preparations by testing for 
the process of heteroexchange. Early studies of g lu tam ate  uptake 
dem onstrated tha t the  add ition  of an alternative substrate cou ld  stim ulate  
the efflux of ano ther substra te  tha t had previously  been  transported  
("loaded") into the synaptosom es (Erecinska and Troeger, 1986). Thus, if 
an analogue is able to undergo  heteroexchange, it can be fu rth er classified 
as a substrate and  d ifferentiated  from  nontransportable inhibitors th a t 
bind to the substrate site on  th e  carrier protein, b u t are n o t translocated. 
Caution m ust be exercised in  these experim ents to insure th a t the in itia l 
in ternal content of radiolabeled substrate is sim ilar w hen  com parisons of 
efflux rates are m ade and th a t the observed efflux occurs specifically v ia  
the transporter and  no t by a  secondary m echanism  (e.g., nonspecific 
leakage, receptor activated event). The specificity of the leakage can be 
confirm ed w ith  a p rev iously  identified  nontransportable  inh ib ito r (e.g., 
d ihydrokainate, (Arriza et al., 1994)) and  the potential con tribu tion  of EAA 
receptors can be excluded th rough  the use of EAA agonists. The process of 
exchange has recently been  used  to dem onstrate that the conform ationally  
constrained analogues L-frans-2,4-PDC (Bridges et al., 1991) a n d  cis-ACBD 
(Fletcher et al., 1991) are transportab le  inhibitors of h igh-affinity  g lutam ate 
uptake in  cerebellar granule cells and  cortical astrocytes (Griffiths et al., 
1994) and that L-frans-2,3-PDC is a nontransportable inhib ito r of the high- 
affinity glutam ate transporter in  forebrain synaptosom es (W illis et al., 
1996).
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Synaptosomal Preparation:
N um erous procedures are available for the  p rep ara tio n  of CNS 
synaptosom es (Robinson, 1998). The follow ing pro tocol, w hich  employs a 
d iscontinuous Ficoll gradient, is based up o n  the m ethod  of Booth and  
Clarke (1978).
Reagents:
H om ogenization Buffer (HB): 10 m M  Tris-acetate, 0.32 M  sucrose, pH  
7.4 (glacial acetic acid)
Ficoll: (Type 400 DL, Sigma) 7.5%, 12.0% , 0.32 M  sucrose, 40 pM  EDTA 
(potassium  salt), p H  7.4 (KOH)
Assay Buffer (AB): 10 m M  Tris-base, 128 m M  N aCl, 10 m M  D-glucose, 5 
mM  KC1, 1.5 m M  N aH 2P 0 4, 1 m M  M gS04, 1 m M  CaCl2, p H  7.4 (glacial 
acetic acid)
Two male Sprague-D aw ley rats w ere sacrificed by rap id  decapitation. 
The brains were dissected free from  the skull, the cerebellum s rem oved ,
and  the tissue placed into =20 m l of ice cold HB. The HB w as decanted and  
the tissue resuspended in  fresh, ice cold HB (10 m l/b ra in ). W h ile  
subm erged in the HB, the forebrains w ere diced in to  sm all pieces w ith
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scissors and  th en  transferred  to a chilled W heaton  glass/glass 
hom ogenizer (15 ml, 0.001"-0.003/' clearance). The tissue  was 
hom ogenized  by h and  (12 strokes) and  th en  centrifuged (1100 g, 3 m in, 4
°C, Sorvall SS-34 rotor). The su p e rn a ta n t was collected an d  recen trifuged  
(14,600 g, 10 m in, 4 °C). The resu lting  pe lle t w as resuspended  in 10 m l 12% 
Ficoll using  a m otorized  Potter-type glass/glass (0.045-0.065 m m  clearance, 
5 strokes) hom ogen izer (Braun) a t 925 RPM. The suspension  w as th e n  
used as the  bottom  layer of a d isco n tin u o u s Ficoll gradient u p o n  w h ich  
was sequentially  layered 10 m l o f 7.5% Ficoll and  10 m l of HB. T he
gradient w as centrifuged (111,000 g, 30 m in , 4 °C, sw inging bucket SW -28 
rotor). The synaptosom al layer th a t form ed a t the interface of the 12% an d  
7.5% Ficoll layers w as collected w ith  a  Pasteur p ipette  and  h o m o g en ize d  
(m otorized Potter-type, g lass/g lass , 0.045-0.065 m m  clearance, 5 strokes, 925 
RPM). The suspension  was gen tly  m ixed w ith = 25 m l of HB an d
centrifuged (28,150 g, 20 m in, 4 °C, SS-34 rotor). The resu lting  pe lle t was 
collected an d  suspended  in AB (0.2 m l/m g  w et wt). This resu lted  in  a 
synaptosom al suspension  of approxim ately  0.2 m g p ro te in /m l. T he 
synaptosom es, w hich  w ere stored on  ice, w ere used for tran sp o rt assays 
w ith in  a few  hours of preparation.
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Synaptosomal Transporter A ctiv ity :
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The follow ing protocol is based  upon  the m ethod of K uhar and  Z arbin  
(1978). A 100 p i a liquo t of the synaptosom al suspension  w as added  to an  
assay tube an d  preincubated a t 25 °C for 5 m in. The assay was 
conveniently  carried ou t in duplicate. Uptake was in itia ted  by the 
addition  of a 100 p i aliquot of AB contain ing  prl]-D -aspartate (1-20 pM , 
final concentration). In  those assays tha t evaluated inh ib ito r activity, the  
100 pi a liquo t of AB contained bo th  the  [^ -D -a sp a r ta te  a n d  po ten tia l 
inhibitors to  ensu re  sim ultaneous addition . Following a 2 m in  incubation 
at 25 °C, the assay tubes were rap id ly  transferred to ice and  quenched by the  
addition of 4 m l of ice cold AB. The synaptosom al suspension  w as quickly 
vacuum  (= 20 m m  H g) filtered th rough  G F /F  (W hatman) glass m icro-fiber 
filters. The assay tubes and filters w ere sequentially rinsed  w ith  an  
additional 4 m l of ice cold AB. The term ination  of the  assay requ ired  less 
than 10 seconds to complete. The filters containing the synaptosom es 
were transferred  to v ials containing liquid scintillation fluid an d  allow ed 
to dissolve for 24 hours. Retained radioactivity w as quantified  by liquid  
scintillation coun ting  and  corrections for nonspecific uptake (e.g., leakage, 
binding) w ere m ade by subtracting the  am ount of [3H]-D-aspartate 
accum ulated a t 4 °C. Initial assays confirm ed tha t up take w as bo th  
sod ium -dependent, by utilizing sod ium -free (choline-substituted) buffer, 
and linear w ith  respect to time an d  p ro te in  content (Bridges e t al., 1991). 
Kinetic constants o f substrates and  inhib itors were determ ined  using  th is 
same procedure and  b y  appropriately  vary ing  the concentrations of [ ^ - D -
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aspartate and  inh ib ito r w ith  respect to Km an d  K; values (for review  see: 
Christensen, 1975).
Measurement o f Synaptosomal Efflux:
Synaptosom es w ere prepared  as described above, except that the final 
suspension w as m ade in a sm aller volume o f AB (0.04 m l/m g  w et wt). A 
9.9 m l aliquot of this suspension  was transferred  to an  assay tube 
containing 100 p i of [^HJ-D-aspartate (2.5 pM , final concentration) and 
incubated a t 25 °C for 15 m in. The synaptosom al suspension  was 
centrifuged (28,150 g, 20 min) to reisolate the  [^J-D -aspartate-containing 
synaptosom es, w hich  were th en  suspended in  5.0 m l of ice cold AB and 
m aintained  in  an  ice bath. The assay was conveniently  carried out in  
duplicate. The exchange assays w ere in itiated  by the addition of 100 pi of 
the suspension to 2.9 ml of AB, which contained  potential substrates 
a n d /o r  m etabolic inhibitors and  was pre-equilibrated to 37 °C. The assay 
was term inated 1-10 m inutes later by rapidly quenching w ith 4 m l of ice 
cold AB followed by vacuum  filtration 20 m m  Hg) through  G F/F  glass 
fiber filters. The assay tubes and  filters w ere sequentially rinsed w ith  an  
additional 4 m l of ice cold AB. The filters con tain ing  the synaptosom es 
w ere transferred to vials contain ing liquid scin tilla tion  fluid and  allow ed 
to dissolve for 24 hours. Retained radioactivity w as quantified by liquid 
scintillation counting and  used to calculate changes in the rate of efflux of 
I^HJ-D-aspartate p roduced by the presence of the  various com pounds. The 
in itial content of the synaptosom es ("0" tim e) w as established by adding 
the 100 pi aliquot of synaptosom es to 2.9 m l of ice cold AB follow ed
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im m ediately by filtering an d  rinsing. This value was de te rm in ed  at the  
beginning, m idd le , and end  of each experim ent to ensure  th a t the a m o u n t 
of [^Hj-D-aspartate in the synaptosom es did no t significantly  change w hile  
being m ain tained  in  the ice bath. To assure that app ropria te  com parisons 
were m ade betw een experim ents, it was verified tha t th e  synaptosom es 
initially contained sim ilar am ounts of [3H]-D -aspartate, as in te rn a l con ten t 
could have effected rates of efflux.
Substrates could  be iden tified  by their ability to increase  the  rate of 
efflux observed in  AB alone. In contrast, non transpo rtab le  inh ib ito rs 
could be identified by both th e ir inability to increase the ra te  of efflux and 
their ability to com petitively  inh ib it the heteroexchange of o ther 
substrates. In  th is respect, w ell characterized non transpo rtab le  inh ib ito rs 
(e.g., d ihydrokainate) could be used  to inhibit substra te-induced  j^Hj-D- 
aspartate efflux and  verified tha t heteroexchange was occu rring  via the  
sod ium -dependen t transporters.
Oocyte Transport: (perform ed in  collaboration w ith  M .P. K avanaugh ,
Vollum  Institu te)
C apped RNA w as transcribed from  linearized plasm ids con ta in ing  the 
coding regions of EAAT1-3 (A rriza et al., 1994). RNA (50 ng) w as injected 
into stage V X enopus  oocytes and  experim ents w ere p erfo rm ed  2-6 days 
later. C urren t recordings w ere  m ade w ith  a tw o-m icroelectrode voltage 
clamp circuit. Electrodes contained 3 M KC1 and had  resistances of 100-500 
kOhm. Oocytes w ere voltage clam ped and  continuously su p erfu sed  w ith  
Ringer recording so lution con ta in ing  (in mM): NaCl, 98.5; CaClj, 1.8;
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MgCl2/1.0; HEPES, 5 (pH  7.5). G lutam ate and analogues w ere bath-applied 
by sw itching to a  so lu tion  containing the com pounds a t the indicated 
concentrations. T he concentration-dependence of the  curren ts induced by 
the com pounds w ere fitted by least squares to the equation 
I=Imax([com p oun d ] /( [c om p ound]+K m). values w ere expressed as mean ± 
S.E.M. from  fits to in d iv id u a l oocytes. N on transportab le  inhibitors were 
co-applied w ith  v a ry in g  concentrations of L -glutam ate, and  Schild analysis 
(A runlakshana an d  Schild, 1959) was perform ed to obtain  estimates of 
inhibitor equ ilib rium  dissociation constants.
Materials:
[3H ]-D -A spartate w as purchased  from NEN (Boston, MA). L-Glutamate, D- 
aspartate, d ihydrokainate , kainate, D,L-p-THA, iodoacetate, potassium  
cyanide, and  Ficoll w ere obtained from Sigma (St. Louis, MO). cz's-ACBD 
w as purchased  from  Tocris (Ballwin, MO). 2,4-MPDC, L-czs-2,4-PDC, L- 
frans-2,4-PDC, L-frans-2,3-PDC, L-czs-2,3~PDC, D-trans-2,3-PDC, D-cz’s-2,3- 
PDC, cis-5-methyl-L-trans-2,3-PDC, L-anfz-endo-3,4-MPDC, L-anti-exo-3,4:- 
MPDC, L-sy«-exo-3,4-MPDC and  L-tra zzs-2,3-ADC w ere synthesized as 
described (Bridges e t al., 1991; Bridges e t al., 1993; Bridges e t al., 1994; 
H um phrey  et al., 1994; Willis et al., 1997; Esslinger e t al., 1998).
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C hapter 3: Synaptosom al Pharm acology of C onform ationally  C onstrained
A nalogues o f L-G lutam ate.
In tro d u c tio n
C onsidering the  im portan t roles played by the EAA transporters in  
both norm al synaptic  transm ission  and in  disease processes, it is n o t 
surprising  th a t significant effort has been directed tow ards delineating the  
pharm acology of th is system. Landm ark studies focused on  establishing 
the existence of a  d istinct system  for glutam ate uptake, and  by u tiliz in g  
EAA analogues an d  o ther acidic amino ad d s, these investigations began to 
define the basic pharm acophore  of glutam ate transport. A  great advance 
tow ards this d irec tion  follow ed the developm ent of conform ationally  
constrained analogues of L-glutamate. Often these com pounds w ere 
designed w ith  the idea of em bedding L-glutam ate, L-aspartate, or po rtions 
thereof in to  a  ring  system  and thus lim iting the total num ber of 
conform ations attainable by the molecule. This strategy led to the  
developm en t an d  identification of uptake inhibitors such  as L-fnms-2,4- 
pyrro lid ine dicarboxylate (L-frans-2,4-PDC), czs-l-am inocyclobutane-1,3- 
dicarboxylate (cz's-ACBD), and  (2S,3S,4R)-2-(carboxycydopropyl)glydne (L- 
CCG-m). The success of these com pounds as selective inhibitors of 
glutam ate u p tak e  led to the developm ent of o ther po ten t, 
conform ationally  constrained  inhibitors and  thus the fu rther re fin em en t 
of the transporte r pharm acophore. In this chapter, several novel series of 
analogues, inc lud ing  the 2,3-pyrrolidine dicarboxylates and 3,4- 
m ethanopy rro lid ine  dicarboxylates, were investigated for their activity at
20
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the high-affinity glutam ate transport system  presen t in ra t fo rebra in  
synaptosom es.
Results and  D iscussion
2,3-Pyrrolidine Dicarboxylates
Four stereoisom ers of 2,3-pyrrolidine dicarboxylate (2,3-PDC) w ere  
synthesized by R apoport-type alkylation of aspartic a d d  as described by 
(H um phrey et al., 1994). W hen L-trans-2,3-PDC, L-cz's-2,3-PDC, D-trans-2,3- 
PDC, and D-czs-2,3-PDC w ere tested for the ability  to inhibit the uptake o f 
[3H]-D-aspartate into forebrain synaptosom es, only the L-trans iso m er 
proved  effective (Table 3.1). U ptake of 5 pM  D -aspartate was decreased to  
24 ± 5% of control (i.e. absence of inhibitor a n d  corrected for leakage a n d  
background, 0.99 ± 0.15 n m o l/m in /m g  p ro tein , n  = 12 sets of duplicate  
assays) w hen  L-fnz?is-2,3-PDC w as in d u d ed  in  the assay at 250 pM. In  
contrast, w hen  the L-cz's, D-trans, and D-czs isom ers were included a t 
sim ilar concentrations, they w ere found to be considerably less effective. 
L-frans-2,3-PDC decreased uptake to 67 ± 2% of control w hen  th e  
concentration of the inhib itor w as reduced to  25 pM. The extent o f 
inhib ition  produced by L-fnms-2,3-PDC a t 25 pM  is com parable to th a t 
observed w ith  several o ther know n glutam ate uptake inhibitors a t th is  
sam e concentration, including  dihydrokainate (52 ± 4% of control), cis-5- 
Me-L-frans-2,3-PDC (80 ± 4% of control), L-czs-2,4-PDC (82 ± 2% of control), 
and  czs-ACBD (88 ± 3% of control) (Table 3.1). A  m ore detailed k inetic  
analysis of the action of L-frans-2,3-PDC is show n  in  Figure 3.1. T he
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representative L inew eaver-B urk  p lo t dem onstrates the activity  of a 
com petitive inh ib ito r, i.e., increasing concentrations of the in h ib ito r  
yielded increased va lues for Km̂ pp w ith no change in  Vmax. The Km an d  
Vmax values for the tran sp o rt of D-aspartate w ere found to be 2.6 ± 0.3 p M  
and 2.3 ± 0.1 n m o l/m in /m g  protein , respectively. A  slope rep lo t (see 
figure 3.1 inset) of th e  values yielded a Kj value of 23 ± 1 pM  for th is
particular experim en t, and  the average of 4 such  determ inations resu lted  
in an average Kj value  of 33 ± 6 pM  (Table 3.2).
3,4-M ethanopyrrolidine Dicarboxylates
The three d iastereom ers of L-3,4-m ethanopyrrolidine dicarboxylate (L- 
MPDC) show n in Table 3.1 w ere prepared  by treating the m ethyl ester o f 
C BZ-L-dehydroproline w ith  ethyldiazoacetate in  the presence of rh o d iu m  
acetate, as described p rev iously  (Bridges e t al., 1994). L-anfz-endo-3,4- 
MPDC, L-zmfz'-e;to-3,4-MPDC and  L-syn-ero-3,4-MPDC w ere each tested for 
the ability to inh ib it the  high-affinity  g lu tam ate transporter. Of the th ree  
isom ers, on ly  L-zznfz'-endo-3,4-MPDC was effective in inhibiting  the u p tak e  
of [3H]-D-aspartate in to  forebrain  synaptosom es. W hen included in  th e  
assay at 250 pM , the tran sp o rt of D -aspartate (5 pM ) was reduced to a lev e l 
that could n o t be d ifferen tiated  from  background. Uptake w as reduced to  
26 ± 3% of control w h e n  the concentration of L-anti-enz2o-3,4-MPDC w as 
decreased to 25pM. The rate  of up take in the control experim ents w as 0.82 
± 0.17 n m o l/m in /m g  p ro te in  (n=6). The extent of inh ib ition  observed 
w ith L-anfz-e«do-3,4-MPDC a t 25 pM  is com parable to tha t p roduced  by L- 
frzz«s-2,4-PDC (19 ± 6% of control), D,L-f3-THA (20 ± 4% of control), L-
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aspartate (18 ± 3% of control) and L -glutam ate (39 + 3% of control) a t th is  
sam e concentration (Table 3.1). The results of m ore detailed  studies o f th e  
inhib itory  action of L-fln£z-endo-3,4-MPDC as a function of co n cen tra tio n  
are show n in  Figure 3.2. The pa ttern  of inhibition exhibited by th e  
L inew eaver-B urke p lo t is consistent w ith  th a t of a com petitive in h ib ito r, 
and  a replot of the values generated a  Kj value of 2.5 ± 0.1 pM . T he  
average of 3 sim ilar determ inations y ie lded  a Kj value of 4.9 ± 2 pM  (Table 
3.2).
2,4-M ethanopyrrolidine Dicarboxylates
In tram olecu lar [2+2] photocyclization w as used to prepare 2,4- 
m ethanopyrrolidine-2,4-dicarboxylate (2,4-MPDC) as described by 
(Esslinger e t al., 1998). At 250 pM , 2,4-MPDC produced an  alm ost com plete  
inh ib ition  of up take  of [3H]-D-aspartate in to  forebrain synaptosom es (4 ± 
0.1% of C ontrol, i.e., 1.1 ± 0.2 n m o l/m in /m g  protein, n  = 16). T ran sp o rt 
w as reduced to 38 ± 1% of Control w h en  the level of 2,4-MPDC w as 
decreased to 25 pM . This inhib ition  is com parable to th a t p roduced by 
sim ilar am oun ts of L-frans-2,4-PDC, L-anti-endo-3,4-MPDC, D,L-(3-THA or 
L-glutam ate (Table 1). A representative L inew eaver-Burk p lo t and  rep lo t 
o f K^pp vs inh ib ito r concentration (inset) for 2,4-MPDC are depicted in  
Figure 3.3. The pa tte rn  of inhibition observed in this analysis w as 
consistent w ith  com petitive inhibition  an d  yielded values of: = 3.8 (D-
aspartate), K; = 5.9 pM , and  a = 3.3 n m o l/m in /m g  protein . Eight su ch  
analyses yielded an  average Kj = 6.8 ± 3 pM  (Table 3.2).
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O n the basis of the Kt values listed in  Table 3.2, the com petitive  
inhibitors of high-affinity g lutam ate tran spo rt could be roughly  d iv ided  
into three categories. Potent analogues could  be considered those s im ila r 
in potency to L-glutam ate an d  L-aspartate (Kj = 1 .5 - 7  pM) and  include L- 
trans-2,4-PDC, D,L-p-THA, L-anfz-enio-3,4-MPDC, and  2,4-MPDC. 
M oderately po ten t analogues w ere m ore com parable in  potency to the well 
know n inhib itor d ihydrokainate  (K; = 30 pM ) and  include cis-ACBD, L- 
trans-2,3-PDC, and czs-5-Me-L-frans-2,3-PDC. Three of the analogues, 
kainate, L-czs-2,4-PDC and L-trans-2,3-ADC, w ere also com petitive  
inhibitors b u t w ere m arkedly  less potent th an  d ihydrokainate, exhibiting 
K; values around  70 pM  and  could  thus be considered  w eak inhibitors.
The constrained analogues, as a result of lim ited structural flexibility, 
were highly  useful in de term in ing  the a rran g em en t of the functional 
groups required  for b ind ing  to the tran spo rte r protein. Energy 
m inim izations of L -glutam ate, L-trans-2,3-PDC, L-frans-2,4-PDC, L-anfz- 
endo-3,4-MPDC and  2,4-MPDC were carried o u t using  SYBYL m olecu lar 
m odeling softw are (Tripos, St. Louis, MO) o n  a  Silicon Graphics Indigo 2 
w orkstation. M olecular superim position  of the analogues was th e n  
conducted using  a three p o in t best fit of the  am ine functionality, a -  
carboxylate carbon and  d istal carboxylate carbon of the m in im iz ed  
structures. Pairw ise com parisons of the th ree  selected atom s w ere m ade 
betw een the conform ations of L-glutam ate an d  each of the analogues, an d  
yielded root m ean  square (RMS) deviations of 0.346 A (L-£rans-2,3-PDC), 
0.391 A (L-£razzs-2,4-PDC), 0.024 A (L-anti-endo-3,4-MPDC), and  0.132 A (2,4- 
MPDC). This procedure is identical to tha t p rev iously  used to define the  
transporter pharm acophore  (Bridges et al., 1991; Bridges e t al., 1993;
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Cham berlin et al., 1998), and  resulted in  structures w ith  a h igh degree of 
overlap and sim ilar functional group arrangem ents (Figure 3.4). F ro m  
this point, additional insigh t into the transporter pharm acophore  w as 
gained by considering the space occupied by the rings o f the  constra ined  
analogues. This volum e represents steric bu lk  not occupied by the  acyclic 
backbone of L-glutam ate b u t that is to lerated  by the transporte r b in d in g  
site. For example, the volum es occupied b y  C4-C5 of L-fra«s-2,3-PDC, C5 of 
L-frans-2,4-PDC, C4-C5 of L-anfz-enzfo-3,4-MPDC, and the  m ethano-bridge  
of 2,4-MPDC m ay indicate regions of the  b ind ing  site that can  
accomm odate the excess steric bulk  of a constrained inhibitor. T hese 
observations will appear m ore significant in  the follow ing chapter on th e  
differentiation of substrate from  nonsubstra te  inhibitors, and w ill n o  
doubt provide fu rther guidance for the developm ent of o ther po ten t an d  
selective inhibitors of the high-affinity g lu tam ate  transporters.
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Table 3.1 Inhib itory  activities o f g lu tam ate  and a sp a rta te  analogues on  the 
synap tosom al up tak e  of [3H ]D -aspartate .
Uptake of 5pM [3H]D-aspartate 
(% of Control)
250 pM  |_____25 pM
C om pound Structure
L-Glutamate 2 ±  2 39 ± 3
L-Aspartate 0 ± 0 18 ± 3
.c o 2h
L-frans-2,3-PDC 24 ± 5 67 ± 2
81 ± 8 n.d.
D-£rans-2,3-PDC n.d.108 ± 8
c o 2h
107 ± 7 n.d.
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Uptake of 5]jM  [5H]D-aspartate 
(% of Control)
250 pM | 25 pM
C om pound Structure
L-zzn£z-endo-3,4-MPDC 0 ± 0 26 ± 3
L-zzn£z-exo-3,4-MPDC 104 ± 6 n.d.
L-syn-exo-3,4-MPDC 111 ± 8 n.d.
2,4-MPDC 4 ±0.1 38 ±1
L-trans-2,4-PDC 0 ± 0 19 ±6
COoH
36 ± 4 82 ± 2
czs-5-Me-L-trans-2,3-PDC 30 ± 2 80 ± 4
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Uptake of 5pM [3H]D-aspartate 
(% of Control)
250 pM
Structure C om pound
25 pM
L-trans-2,3-ADC 53 ± 5 96 ± 6
cz's-ACBD 26 ± 1 88 ±3
H,N
0 ± 0 20 ± 4OH
, . ^ OH
CH
Dihydrokainate 25 ± 2 52 ± 4
CH.
Kainate 39 ± 4 n.d.
Synaptosom al up take  of pH ]-D -asparta te  is reported  as m ean  % of control 
± s tandard  deviation. The data  for each com pound w as based  on a t least 
three duplicate  determ inations each from separa te  synap tosom al 
p reparations. A verage control up take  of pH ]-D -asparta te  in the 
synaptosom al p rep ara tio n s w as 0.97 n m o l/m in /m g  protein . The assays 
were perform ed as described in  M ethods and M aterials an d  have been 
corrected for nonspecific up take and  leakage, n.d. denotes n o t detected.
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Figure 3.1 C om petitive inhibition of [3H ]-D -aspartate uptake into
synaptosom es by  L-£rans-2,3-PDC.
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R epresentative L inew eaver-B urk p lo t dem onstra ting  the com petitive  
inhibition  of [3H]-D-aspartate up tak e  into forebrain synaptosom es by L- 
trans-2,3-PDC. The inset shows a rep lo t of K^pp vs [L-frans-2,3-PDC]. T he 
plots show n w ere generated u sing  the k-cat kinetic program  (BioM etallics 
Inc., Princeton, NJ) w ith  w eighting based on  constant relative error, and  
yielded values of: = 2.6 ± 0.3 pM  (D-aspartate), Vmax = 2.3 ± 0 . 1
n m o l/m in /m g  p ro tein , and Kj = 23 ± 1.
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Figure 3.2 C om petitive inhibition of [3H ]-D -aspartate uptake into
synaptosom es by  L-zz«fz-endo-3,4-MPDC.
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R epresentative L inew eaver-B urk plot dem o n stra tin g  the com petitive  
inhib ition  of [3H]-D-aspartate up take  into fo rebrain  synaptosom es by L- 
anfz'-endo-3,4-MPDC. The inset show s a rep lo t of Kmapp vs [L-anti-endo-3,4:- 
MPDC]. The p lots show n w ere generated u sing  the k-cat kinetic p rog ram  
(BioMetallics Inc., Princeton, NJ) w ith  w eigh ting  based on  constan t 
relative error, and  yielded values of: Km = 2.7 ± 0.3 pM  (D-aspartate), = 
1.7 ± 0.1 n m o l/m in /m g  protein , and  Kj =2.5 ± 0.1.
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Figure 3.3 C om petitive inhibition of [3H ]-D -aspartate uptake into
synaptosom es by  2,4-MPDC.
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R epresentative L inew eaver-Burk p lo t dem onstra ting  the co m p e titiv e  
inh ib ition  of fH j-D -aspartate uptake into forebrain synaptosom es by  2,4- 
MPDC. The inset shows a rep lo t of vs [2,4-MPDC]. The plots sh o w n  
w ere generated using the k-cat kinetic program  (BioMetallics Inc., 
Princeton, NJ) w ith  w eighting based on  constant relative error, and  
yielded values of: = 3.8 ± 0.5 pM  (D-aspartate), Vmax = 3.3 ± 0.2
n m o l/m in /m g  protein, and  Kj = 5.9 ± 1.
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Table 3.2 IQ values for inhibitors of synaptosom al pH ]D -aspartate  uptake.
Com pound (pM)
L-Glutamate 4.9 ± 1
L-Aspartate 1.7 ± 0.6
L-£rarcs-2,4-PDC 1.5 ± 0.5
D,L-P-THA 2.0 + 1
L-an ti-endo-3,4-MP D C 4.9 ± 2
2,4-MPDC 6.8 ± 3
Dihydrokainate 28 + 2
cz's-ACBD 30 ± 2
L-frans-2,3-PDC 33 ± 6
czs-5-Me-L-frzzjis-2,3-PDC 37 ± 6
Kainate 59 ± 6
L-czs-2,4-PDC 66 ± 6
L-frans-2,3-ADC 78 ± 6
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Table 3.2: The values reported in this table represent the average Kj values 
± standard deviation as determ ined in at least 3 separate Lineweaver-Burk 
analyses (see representative plots. Figures 3.1 - 3.3) of the inhibiton of the 
Na"-dependent uptake of [3H]-D-aspartate into synaptosomes. The plots 
were prepared using the k-cat kinetic program  (BioMetallics Inc., Princeton 
NJ) with weighting based on constant relative error. K; values were 
estimated on the basis of a replot of app values.
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Figure 3.4: M olecular m odeling o f the proposed g lutam ate tran sp o rte r 
b ind ing  conform ations of L -glutam ate, L-£rans-2,3-PDC, L-£rans-2,4-PDC, L- 
anti-endo-3,4-MPDC, and 2,4-MPDC w as perform ed on a Silicon G raphics 
w orkstation using  SYBYL m odeling  softw are (Tripos, St. Louis, MO). A ll 
molecules are m inim ized  conform ations w ith  hydrogens om itted  for 
clarity. M olecular com parisons w ere  achieved using a three po in t fit of
the a-carboxylate carbon (darkest gray represents carbon backbone), a m in o
group (m edium  gray) and distal carboxylate carbon (lightest gray depicts 
carboxylate moieties), and  yielded an  average RMS deviation  of 0.32 ± 0.12
A).
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Chapter 4: D ifferen tia tion  of Substrate and N o nsubstra te  Inhibitors of 
Synaptosom al T ransport
In troduction
M uch of ou r understand ing  of the contribu tion  o f sod ium -dependen t, 
high-affinity glutam ate transporters to EAA physiology and  pathology has 
em erged as a consequence of the ability to pharm acologically  m an ipu la te  
transporter activity. The m ajority of studies characterizing  glutam ate 
transport inhibitors, how ever, have often neglected to  address w hether o r 
not the selective blockers are also transported, i.e., w hether they also act as 
substrates for the transporter. W hile this om ission  has been partially 
addressed by  electrophysiologically recording substrate-induced currents in  
voltage-clam ped oocytes expressing cloned transporte rs (Arriza et al., 
1994), it rem ains a significant obstacle in  m ore com plex physiological 
preparations obtained directly from CNS tissues (e.g., synaptosom es, tissue 
slices, p rim ary  cell culture). In the present study, w e  test the hypothesis 
that transporter-m ediated heteroexchange can be read ily  used in  a classical 
synaptosom al p reparation  to distinguish  transportab le  from  n o n ­
transportable inhibitors.
A library of conform ationally constrained g lu tam ate  analogues (see
Table 3.1 and  Table 4.1) was brought to bear u p o n  the  synaptosom al
glutam ate transport system s for the purpose of add ressing  two key issues:
36
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the m olecular d ifferentiation of substra te  and- nonsubstra te  inhib itors, and  
the com parison  o f this extensively used  physiological p rep a ra tio n  to the  
activities of the  c loned  g lu tam ate  transporters. It w as d em o n stra ted  th a t 
the process of transporte r-m ed ia ted  heteroexchange, in  w hich  a n  
externally app lied  substrate stim ulates the  efflux of an  in te rn a l 
(radiolabeled) substra te  th a t h a d  been previously  sequestered  in  the  
synaptosom es, can  be exploited to rapidly differentiate substrates f r om 
nontransportab le  inhibitors. A  num ber of po ten t inh ib ito rs w ere 
identified  tha t sha red  sim ilar position ings of their functional groups, yet 
exhibited m arked ly  different capacities to serve as substra tes for th e  
transporter. These analogues w ere  th en  used in  m o lecu lar m o d e lin g  
studies to refine o u r  pharm acophore  m odel of the substra te  b ind ing  site 
on the transporter. Interestingly, the  resulting  pharm acological profile of 
substrates and  non transpo rtab le  inhibitors also dem o n stra ted  th a t th e  
synaptosom al p repara tion  exhib ited  the greatest correspondence w ith  
EAAT2, a tran sp o rte r believed to be prim arily  of glial o rig in  (for rev iew  
see: G egelashvili a n d  Schousboe, 1997).
Results an d  D iscussion
The conform ationally  constra ined  com petitive inh ib ito rs listed in  
Table 4.1 w ere tested  as po ten tia l substrates by assaying th e ir  ability to
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exchange w ith , an d  stim ula te  the efflux of, a radiolabeled substrate f r o m  
inside the synaptosom es. Thus, synaptosom es w ere incubated w ith [3H ]-D - 
aspartate, reisolated by u ltracen trifugation , resuspended ([3H]-D-aspartate 
content, 1152±65 p m o l/m g  protein) an d  then  d ilu ted  30-fold into assay 
buffer at 37°C in  the  presence an d  absence of potential substrates. 
A nalogues w ere tested a t 100 pM  and , to ensure comparable levels o f 
occupancy of the  tran spo rte r b in d in g  sites, at a concen tra tion  
approxim ately 10-fold g rea ter than  the BQ values w ith  w hich they inhibited 
uptake. The extent of efflux w as quantified  over a two m in  period. T he  
values w ere corrected for the  efflux w h ich  occurred in the absence o f 
inhibitor (228 ± 8 pm ol /m g  p ro te in /2  m in) and  are sum m arized in  Table 
4.1. The analogues exhibited a  w ide range  of substrate activities tha t d id  
n o t necessarily correlate w ith  the  ability of the com pounds to bind to th e  
transporter. For exam ple, L -glutam ate and  'L-anti-end.o-3,4rbA¥DG w ere
equally effective a t inh ib iting  uptake (BQ values * 5 pM), although L-anti- 
endo-3,4-MPDC exhibited only a th ird  of the substrate activity of L- 
glutam ate. In  contrast, 2,4-MPDC (BCj = 6.8 pM) proved to be a lm o st 
equipotent w ith  L -glutam ate in  stim u la ting  exchange, indicating th a t 
conform ational restric tion  does no t necessarily convey a low  substrate 
activity. Interestingly, czs-ACBD and L-cz's-2,4-PDC (Kj = 30 pM  and 66 pM , 
respectively) also produced a m arked increase in  the efflux of pPQ-D- 
aspartate w hen  p resen t a t concentrations sufficient enough to ensure h ig h
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levels of binding. These results suggest that even m odera te-to -w eak  
inhibitors can be effectively translocated once bound to the tran sp o rte r  
substrate site. A lthough  kainate, dihydrokainate, L-fratts-2,3-PDC, and  
cfs-5-Me-L-£rans-2,3-PDC were iden tified  as com petitive inhib itors, these  
com pounds did no t produce levels of efflux that w ere significantly  
different from  w hat was observed in  the absence of in h ib ito r. 
A dditionally, w hen  included  in th e  efflux assay in com bination w ith  L- 
glutam ate, bo th  dihydrokainate and  L-fmns-2,3-PDC effectively a tten u a ted  
glutam ate-m ediated exchange, consistent w ith the action of 
nontransportab le  inhibitors. S im ilar results were observed in  m o r e  
detailed studies that exam ined the tim e course with w hich the  substrates 
and nonsubstrate inhibitors altered th e  efflux of [3H]-D-aspartate from  th e  
synaptosom es. As illustrated in  Figure 4.1A, little or no efflux o f 
radiolabel w as observed w hen  the synaptosom es were m ain ta ined  a t 4°C
(< 40 m in). H ow ever, w hen the synaptosom es were dilu ted  in to  assay 
buffer a t 37°C in the presence of L-glutam ate (10 pM), the resu lting  efflux 
of [3H]-D-aspartate w as m ore than  2-fold greater than  that observed in  
assay buffer alone. O n the  other h and , L-frans-2,3-PDC (300 pM) n o t on ly  
failed to stim ulate heteroexchange b y  itself, b u t it also reduced the level of 
glutam ate-m ediated heteroexchange w hen  it was combined in  the  assay 
w ith  this substrate (Figure 4.1A).
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The specificity of the exchange process, w h ic h  is critical to evaluating  
the utility of this approach for identifying g lu tam ate  transporter substrates 
and inhibitors, was evaluated by conducting  a parallel series of 
experim ents w ith  GAB A. As show n in F igure 4.1 A  and Figure 4.2, the  
efflux of [3H]-D-aspartate was unaffected by the  inclusion  of GABA (50 pM ) 
in the d ilu tion buffer. Conversely (Figure 4.1B a n d  Figure 4.2), the efflux 
of radiolabel from  synaptosom es contain ing  [3H]-GABA (3887±263 
p m o l/m g  protein) w as m arkedly enhanced by th e  presence of GABA (50
pM , i.e., « 10 x Ki) in  the assay buffer, b u t n o t by  L-glutam ate (10 pM ). 
Similarly, GABA-m ediated hom oexchange w as n o t  inhibited by L-trans-
2,3-PDC (300 pM). A dditional experim ents dem onstra ted  that the efflux of 
[3H]-D-aspartate or [3FI]-GABA from  the synaptosom es was no t altered by 
the presence of NM DA (100 pM ), kainate (100 pM ), AMPA (100 pM ), or 
frans-ACPD (100 pM), ruling ou t the p o ten tia l contribution of EAA 
receptors to the exchange process (Figure 4.2).
The validity of this approach rests on the p re ten se  that the observed 
synaptosom al efflux of [3H]-D-aspartate tha t occurs as a result of an  
externally applied com pound represents transporter-m ed ia ted  exchange of 
in ternal for external substrate. That this w as indeed  occurring in  the 
presen t experim ents is supported by the d em o n stra tio n  that: i) efflux was 
stim ulated in  a substrate-specific m anner (e.g., L-glutam ate and  L- 
aspartate, but no t GABA, are active), ii) efflux w as unaffected by the EAA
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recep tor agonists NMDA, KA, AM PA or trans-ACPD, and  iii) substrate- 
induced  increases in  efflux could be a ttenuated  by analogues iden tified  
electrophysiologically  and biochem ically as non transportab le  in h ib ito rs  
(e.g., d ihydrokainate , L-frans-2,3-PDC) (Johnston et al., 1979; A rriza et al., 
1994). T hus, com pounds could be selectively tested for tw o d istinct steps 
in  the  synaptosom al uptake process: com petitive inh ib ition  of up take  as 
an  ind icator of b ind ing  and the stim ula tion  of heteroexchange as a 
m easure  of substra te  activity.
C om parisons of these tw o properties w ith in  the context of ou r library 
of conform ationally  constrained analogues suggest th a t the ability  of a 
com p o u n d  to b ind  to the transporter does n o t necessarily dictate its 
activity  as a substrate. This is readily exem plified by L-glutam ate, 'L-anti- 
endo-3,4-MPDC, and  2,4-MPDC, each of w hich com petitively  in h ib ited  
up take  w ith  com parable values ( = 5 - 7  pM ). Thus, w hile these
com pounds appear equal in their ability to b ind  to the transporter, 2,4- 
MPDC and  L-anfz-endo-3,4-MPDC w ere translocated only about 80% and  
35% as effectively as L-glutamate, respectively. Such differences in  
substra te  activity  w ere not lim ited to ju st those com pounds exhibiting Kt 
va lues sim ilar to L-glutamate. For exam ple, L-aspartate, L-frans-2,4-PDC 
and  D,L-p-THA each inhibited the uptake of [3H ]-D -aspartate m ore p o ten tly  
th an  L -glutam ate (e.g., K; values = 1 . 5 - 2  pM), yet varied  greatly in  th e ir  
ability  to s tim u la te  exchange (e.g., 80%, 60% and  47% the activity of L-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
42
glutam ate, respectively). Even m ore su rp ris in g  th an  the  substrate  activ ity
of these po ten t inhibitors w as the find ing  th a t th e  m odera te-to -w eak
inhibitors (Kj = 30-70 pM) also included bo th  substrates (czs-ACBD, L-czs-
2,4-PDC, L-£ra«s-2,3-ADC) and  nonsubstra te  inh ib ito rs (e.g., czs-5-Me-L- 
frans-2,3-PDC, L-frans-2,3-PDC, d ihydrokainate  and kainate). Thus, w h ile  
a com pound like L-czs-2,4-PDC (Kj = 66 pM ) m ay  be considered  inferior in  
its ability to in itially  bind to the  substrate site of the transporter, once it  
occupies this site, it can be translocated as effectively as substrates such as 
L-aspartate. These findings are also consistent w ith  p rev io u s 
dem onstra tions th a t L-£ra«s-2,4-PDC and  czs-ACBD can stim ulate  th e  
efflux of [3H ]-D -aspartate from  cultured  cerebellar granule cells (Griffiths et 
al., 1994). Likewise, L-fra«s-2,4-PDC has been  show n to exchange w ith [3HJ- 
L-glutam ate in  reconstitu ted liposom es con ta in ing  g lu tam ate  transporters 
(Volterra et al., 1996).
W hile n u m ero u s chem ical properties m ay  influence w h e th er or no t a 
com pound tha t b inds to the transport p ro te in  is also translocated  by th e  
up take  system , the  present library of analogues dem onstra tes th a t 
conform ational restriction  does n o t inheren tly  d ifferentiate  transportable  
from  nontransportab le  inhibitors. For exam ple, the  co n fo rm a tio n a l 
rig idity  p roduced  th rough  the incorporation  of d istinc t pyrro lid ine- 
containing, bicydic ring  system s in  2,4-MPDC an d  L-zm£z-endo-3,4-MPDC 
resu lted  in a sim ilar position ing  of th e ir functional groups an d
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com parable Kj values as com petitive inhibitors, ye t 2,4-MPDC p ro v ed  to be 
a very good substrate, w hile L-zzn£z'-endo-3,4-MPDC d id  not. Indeed, in a 
previous study w ith  Xenopus oocytes, L-anti-endo-3,4r-M?DC w as found to 
be a non transportab le  inhibitor (Kj = 1.6 pM) a t EAAT-2 (Esslinger e t al., 
1998). A dvantageously, the identification of represen tative  transportab le  
and nontransportab le  inhibitors tha t are conform ationally  rig id  allows 
pharm acophore m odeling  to be extended beyond the process of b inding  
and tow ard  an in itia l delineation of the underly ing  chem ical properties 
tha t influence substrate  activity. To accom plish this, energy -m in im ized  
conform ations of L-glutam ate, and representative substrates (2,4-MPDC, L- 
trans-2/4-PDC and czs-ACBD) and non transportab le  inhibitors (L-frzzzzs-2,3- 
PDC and  L-anfz-e«do-3,4-MPDC) w ere first identified an d  th en  
system atically overlaid  using  a Silicon Graphics w orkstation  an d  SYBYL 
m odeling  software (Tripos, St. Louis).
The spatial positionings of the two negatively  charged carboxylate 
functionalities (designated in red  in Figure 4.5) and  the positively  charged 
am m on ium  functionality  (designated in pu rp le  in  Figure 4.5) of each 
analogue were com pared  in a three-point best fit analysis to  identify 
conform ers exhibiting the  greatest degree of overlap. This approach  is 
identical to that used  previously  to characterize th e  glutam ate tran sp o rte r 
b ind ing  site pharm acophore  (Bridges et al., 1993; C ham berlin  e t al., 1998; 
Esslinger e t al., 1998). As all substrates m ust first b ind , the sam e conform er 
of g lu tam ate was u sed  as a  starting po in t in b o th  m odels. As show n  in
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Figure 4.5A, the substrates (L-£rans-2,4-PDC (red), 2,4-MPDC (yellow), and  
czs-ACBD (white)) exhibited a high degree of overlap (e.g., RMS d ev ia tio n  
of 0.42 ± 0.17 A) w ith the m in im ized  L-glutam ate (green) conform ation  of 
the curren tly  proposed pharm acophore. Sim ilarly, the inh ib ito rs  
identified as non-substrates (L-frans-2,3-PDC (orange) a n d  L-anti-endo-3,4:- 
MPDC (light blue)) also overlaid w ell w ith  this conform ation  of L- 
glutam ate (green), as show n  in Figure 4.5B. W hen th e  overlays of bo th  
substrates and  non-substrate inhibitors w ere com pared (Figure 4.5C), it w as 
noticed th a t w hile the functional group positioning  w a s  very  sim ilar (e.g., 
RMS deviation of 0.32 ± 0.12 A), regions of excess steric vo lum e associated 
w ith the carbon backbones of the nonsubstrates cou ld  be identified th a t 
were distinct relative to the space occupied by the backbones of th e  
substrates. These regions (depicted in  yellow  fram ew ork  in  Figure 4.5D) 
become m ore obvious w h e n  m olecular volum es of th e  substrates (Figure 
4.5A) are subtracted from  those of the nonsubstrates (F igure 4.5B). W  e 
suggest tha t ow ing to the  rig idity  of the  com pounds, it is likely that steric 
excess in  these specific positions represents a d e te rm in in g , or at least 
predictive, factor in w h e th er or not the analogues c a n  be translocated. 
Thus, w hile the  sim ilar positionings of the charged functionalities allow s 
binding to occur, the excess volum e occupied by the backbones of th o se  
analogues identified as non transportab le  inhibitors m a y  sterically in terac t 
in an unfavorable m an n er w ith  specific dom ains o n  the tran spo rte r 
protein tha t participate in translocating substrates once th e y  are bound.
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The actions of the  analogues w ere  also exam ined in  X enopus  oocytes 
expressing cloned h u m an  g lu tam ate  transporters (perform ed in  
collaboration w ith  M.P. K avanaugh , V ollum  Institute). O w ing to th e  
electrogenic natu re  of the translocation  of L-glutam ate an d  associated 
counter ions by the EAATs, substrates could be readily  differentiated  from  
nonsubstrates based upon  the ability to produce an  electrical c u rre n t 
(Arriza et al., 1994). W hen 2,4-MPDC was applied  to vo ltage-clam ped 
oocytes expressing EAAT2, this analogue induced curren ts in  a dose- 
dep en d en t m anner (Figure 4.3A) th a t yielded a va lue  of 45 pM. T his 
analogue proved to be an  excellent substrate of EAAT2, as it exhibited a n  
Imax value  15% greater than  th a t o f L-glutam ate itself (Table 4.2, (Esslinger 
et al., 1998)). W hile 2,4-MPDC also proved to be a substrate  of bo th  EAAT1 
and  EAAT3, in  these instances it exhibited values abou t tw o-fold 
greater th an  those observed a t EAAT2 and 1 ^  values of only  about h a lf  
those of L-glutam ate (Table 4.2).
In contrast to the actions of 2,4-MPDC, application of 30 pM  L-trans-2,3- 
PDC to oocytes expressing EAAT2 d id  no t induce a cu rren t (Figure 4.3B). 
H ow ever, w hen co-applied w ith  30 pM  L-glutam ate, th is analogue 
significantly reduced the substrate-induced currents no rm ally  observed 
w ith  L-glutam ate alone. Schild analysis of this inh ib ition  w as consisten t 
w ith  a com petitive m echanism  an d  yielded a Kd of 16 pM  (Figure 4.3C). 
F urtherm ore , L-frans-2,3-PDC d id  no t induce any curren ts in  oocytes
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expressing EAAT1 or EAAT3 (Kd>300 pM ), and  w as ineffective at 
inhibiting glutam ate-induced currents at these subtypes.
The electrophysiological characterization o f transport into oocytes 
expressing hum an  EAAT1, EAAT2 or EAAT3 prov ided  an  a lterna tive  
approach  to corroborate our conclusions regard ing  substrate activity as 
de te rm ined  by heteroexchange, as w ell as a strategy to com pare th e  
pharm acological profile of synaptosom al up take  to tha t of the in d iv id u a l 
transporte r subtypes. U sing a select series of com pounds tha t included 
both transportable  and  non transportab le  inh ib ito rs, w e found  a good 
correspondence betw een the ability of an  analogue to stim ulate th e  
synaptosom al efflux of [3H]-D-aspartate and its ability to induce substrate- 
m ediated  currents in the oocytes, particularly  those expressing EAAT2 
(Figure 4.4). At one extrem e, 2,4-MPDC exhibited an  1 ,^  in  EAAT2- 
expressing oocytes greater than  th a t of L-glutam ate itself and  proved to be 
one of th e  m ost effective analogues in  the synaptosom al exchange assays 
(Table 4.2). A t the other extrem e, L-fra«s-2,3-PDC (and dihydrokainate) 
was fo u n d  to be inactive at e ither p roducing  currents in  these sam e 
oocytes o r stim ulating the  efflux of [3H]-D-asp artate from th e  
synaptosom es (Table 4.2), yet w as capable of com petitively  blocking the  
norm al g lu tam ate-m ediated  response in  both  system s. In the instance of 
the analogues that w ere identified  as partial substrates in  the  exchange 
assays (e.g., L-frans-2,4-PDC and  D,L-(3-THA), p rev ious studies h a v e
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dem onstrated  that these sam e com pounds produce in term ediate  1̂  
values in  oocytes expressing EAAT1, EAAT2, and EAAT3 (Arriza et al.,
1994). It is 2,4-MPDC, L-trans-2,3-PDC, and  dihydrokainate, how ever, th a t 
p rov ided  the m ost com pelling evidence linking synaptosom al 
pharm acology w ith  EAAT2, particu larly  w ith in  the context of substrate 
activity (Figure 4.4, Table 4.2). W hile com parisons of relative va lu es 
and efflux rates are adm ittedly  qualitative in  nature, L-fnzns-2,3-PDC an d  
d ihydrokainate  w ere essentially inactive a t EAAT1 and  EAAT3, yet 
effective non transportab le  inh ib ito rs of both  EAAT2 and th e  
synaptosom al system . A nother non transportab le  inhibitor of EAAT2, L- 
anfz-endo-3,4-MPDC (Esslinger et al., 1998), produced an efflux rate th a t 
w as only a th ird  of tha t produced by L-glutam ate. 2,4-MPDC, on the o th e r  
hand , p roved to be an excellent substrate of both EAAT2 and th e  
synaptosom es, yet produced 1 ^  values a t EAAT1 and EAAT3 that w ere  
only about half those of L-glutamate.
W hen sim ilar attem pts w ere m ade to com pare the kinetic constants in  
the two system s, som e difficulties arose because the recordings of th e  
substrate-induced currents in  the EAATs typically yielded Km values, w hile 
the synaptosom al inhibitory assays resulted  in Kj constants. T h is 
com plication w as avoided, how ever, in  the instance of th e  
non transportab le  inhibitors, as both  approaches yielded Kj values. In  th e  
p resen t study  w e found that the Kj values for L-frans-2,3-PDC an d  
dihydrokainate  very sim ilar to one ano ther w ith in  each system , bu t abou t
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3-fold less in  the  oocytes th an  in  the synaptosom es. Such a rela tionsh ip  is 
consistent w ith  recent s tud ies dem onstra ting  th a t d ihydrokainate , kainate , 
and D,L-f/zreo-p-benzyloxyaspartate (TBOA), all of w hich  are n o n ­
transportable inhib itors a t EAAT2, also exhibited  low er Kj values w h e n  
characterized in  oocytes as com pared to m am m alian  cells expressing th e  
transporters (A rriza et al., 1994; Shim am oto e t al., 1998).
The conclusion  that EAAT2 corresponds m o st closely w ith  th e  
synaptosom al system  is quite  in teresting  in  v iew  of the general 
p resum ption  th a t EAAT2 (rat hom ologue GLT-1), is th o u g h t to be chiefly 
expressed in  astrocytes (for rev iew  see: G egelashvili and  Schousboe, 1998). 
The findings suggest th en  that e ither the  synap tosom al p rep a ra tio n  
contains glial fragm ents possessing functional transporte rs , o r tha t a 
separate yet un iden tified  g lutam ate tran sp o rte r  subtype exists in  n e u ro n s  
that shares a sim ilar pharm acology w ith  EAAT2. W hile th e  latter can n o t 
be ruled out, num erous reports indicate b o th  the  hete rogeneous na tu re  of 
synaptosom es (H enn et al., 1976; N ak am u ra  e t al., 1993) and  tha t th e  
p redom inan t transport activity in this p rep a ra tio n  is "EAAT2-like" in  its 
pharm acology (Dowd et al., 1996; G egelashvili an d  Schousboe, 1998). 
Significantly, it has also been  dem onstra ted  th a t synaptosom es prepared  
from  mice deficient in  GLT-1 exhibit a  m arked  loss in  the  ability to 
transport L -glutam ate (Tanaka et al., 1997). R egardless of the exact 
subtype(s) p resen t in the synaptosom es, o u r da ta  clearly  indicate th a t 
w ith in  the context of the know n tran sp o rte r  subtypes, the p roposed
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pharm acophore (as w ell as the synaptosom al assay system) should  be 
considered as a w ork ing  m odel for the  EAAT2 subtype. In  th is regard, 
prelim inary  m odeling  studies ind icate  th a t m ore recently iden tified  
inhibitors of EAAT2 (e.g., T-BOA, (±)-f/zm>-3-methylglutamate, 2S,4R-4- 
m ethylglutam ate, an d  (±)-4-m ethyleneglutam ate) (V andenberg e t al., 1997; 
Shim am oto et al., 1998), also fit w ith in  the proposed pharm acophore. N o t 
only was there significant functional group overlap in  each case, b u t th e  
m odifications to the g lu tam ate /asp arta te  backbone p resen t in  those  
com pounds identified  as non-transportab le  inhibitors of EAAT2 (e.g., T- 
BOA, (±)-ffrreo-3-m ethylglutam ate, (2S,4R)-4-m ethylglutam ate
(V andenberg e t al., 1997; Shim am oto e t al., 1998), overlapped w ith  those  
regions depicted in  the m odel (Figure 4.5) as tolerated for b ind ing  b u t n o t 
translocation. As these m odels are refined  for each transporter subtype, 
they  should  prove valuable in  the design  of m ore selective substrates and  
non transportab le  inhibitors, as w ell as identify im portan t functional 
dom ains th a t m u st be incorporated in to  evolving structural m odels of the  
transporters.
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Table 4.1: Kj values a n d  Exchange Rates for T ransport Inhibitors
C om pound K,
(pM)
C oncentration
(pM)
Exchange Rate 
(pmol/mg protein/2  min)
L-Glutamate 4.9 ± 1 100 362 ± 12
50 344 ± 16
10 316 ±22
2,4-MPDC 6.8 ± 3 100 282 ± 28
75 280 ± 30
L-Asp artate 1.7 ± 0.6 100 278 ± 16
20 266 ±22
czs-ACBD 30 ± 2 100 266 ± 4
300 270 ± 8
L-czs-2,4-PDC 66 ± 6 100 206 ± 16
500 260 ±22
L-trzms-2,4-PDC 1.5 ± 0.5 100 250 ± 28
15 208 ± 28
D,L-p-THA 2.0 ± 1 100 172 ± 24
20 162 ± 16
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Com pound Is
(pM)
Concentration
(pM)
Exchange Rate 
(pmol/mg protein/2  min)
L-£rans-2,3-ADC 78 ± 6 100 146 ± 14
800 156 ± 26
L-anfi-endo-3,4-MPDC 4.9 ± 2 100 120 ± 20
50 120 ± 18
Kainate 59 ± 6 100 0 ± 1.5
600 0 ± 0
czs-5-Me-L-£rzms-2,3-PDC 37 ± 6 100 3 ± 6
350 0 ± 0
Dihydrokainate 28 ± 2 100 0 ± 3
300 11 ± 6
Dihydrokainate + 300 60 ± 12
L-Glutamate 10
L-£rzzns-2,3-PDC 33 ± 6 100 3 ± 6
300 19 ± 6
L-£rzzns-2,3-PDC + 300 76 ± 16
L-Glutamate 10
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Table 4.1: Kj values in  this table are reported  as th e  m ean  ± standard
deviation  of a t least 3 separate L inew eaver-B urk analyses w hich w ere 
carried o u t as described in  C hapter 3. The synap tosom al efflux of [3H]-D- 
aspartate induced  by the inhib ito rs was quantified  o v e r a 2 m in  period at 
37°C and  w as corrected for the efflux that occurred in  the  absence of added 
com pound (228 ± 8 p m o l/m g  p ro te in /2  m in). Inh ib ito rs w ere tested both  
at 100 pM  and , to en su re  com parable levels of tran sp o rte r  binding, at 
concentrations approxim ately  10 times greater th a n  the Kt values for 
w hich they  inh ib ited  [3H]-D-aspartate uptake. T he rates of efflux are 
reported as m ean  ± S.E.M. from  at least 4 separa te  de te rm ina tions 
conducted in duplicate.
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Figure 4.1: The time course for the efflux of either A) [3H ]-D -aspartate or B) 
[3H]-GABA is reported as a percentage of the initial synaptosom al co n ten t 
(1552±65 pm ol [3H]-D-aspartate /  m g  pro tein  or 3887±263 p m o l [3H]-GABA 
/  m g  protein). W hile the efflux of [3H]-substrate was no t detected from  
synaptosom es m ain tained  a t 4°C, the inclusion of L -glutam ate o r GABA 
at 37°C caused an efflux of over 50% of synaptosom al pH]-D-aspartate o r 
[3H]-GABA, respectively. In  contrast, GABA did no t stim ulate the  efflux of 
pHj-D-aspartate nor d id  L -glutam ate potentiate the release of [3H]-GABA. 
Interestingly, L-£ra«s-2,3-PDC d id  no t participate in heteroexchange on  its 
ow n b u t it did significantly a ttenua te  the efflux of [3H]-D-aspartate caused 
by the inclusion of L-glutam ate. L-£rans-2,3-PDC had  no  effect on  the  
efflux of [3H]-GABA. Values are reported  as m ean ± S.E.M. from  at least 4 
determ inations conducted in  duplicate. Statistical com parisons w ere 
perform ed using the A lternate  W elch t-test (GraphPad softw are, S an  
Diego, CA): * pc.0001 versus C ontrol efflux; t  pc.Ol vs L -G lutam ate- 
induced  efflux.
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Figure 4.2: Transporter-Specific Efflux o f  [^Hj-Substrate from  Synaptosom es
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Figure 4.2: Efflux o f radiolabeled substrate from  synaptosom es co n ta in in g  
either [3H]-D -aspartate or [3H]-GABA was determ ined  as described in  
Chapter 2 and  is expressed as percent of C ontrol (i.e., efflux over a 2 m in  
interval a t 37°C in  the absence of uptake inhibitors). Initial con ten t of 
synaptosom es w as 1552 ± 62 pm ol [3H]-D-aspartate /  m g p ro te in  or 3887 ± 
263 pm ol [3H]-GABA /  m g  protein. Control efflux rates w ere 114 ± 4 p m o l 
/  m in /  m g pro tein  for [3H]-D-aspartate and  354 ± 30 pm ol /  m in  /  m g  for 
[3H]-GABA. V alues are reported  as m ean ± S.E.M., n  = 4-57 duplicate  
determ inations. Statistical com parisons w ere m ade using  an  A lte rna te  
W elch t-test (G raphPad software, San Diego, CA); * p<0.0005 v e rsu s  
Control efflux.
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Figure 4.3: Electrophysiological Recordings of A nalogues in  Xenopus Oocytes 
Expressing EAAT2.
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Figure 4.3: Actions o f transported  and non transported  analogues a t
EAAT2 w ere determ ined  as described in  Chapter 2. A. C urrents induced  
by application of g lu tam ate  or 2,4-MPDC (duration indicated by bar above 
trace) in  a represen tative  X enopus  oocyte expressing EAAT2. 2,4-MPDC 
induced a dose-dependent and  saturable curren t w ith  a of 45pM  
(m em brane potential = -25 mV). B. Co-application of L-fra«s-2,3-PDC (30 
pM) reduced g lu tam ate-induced  curren t w ithout inducing  curren t on its 
own. C. Schild analysis of the effect of L-frans-2,3-PDC on g lu tam ate  
currents revealed com petitive  antagonism , Kd = 16 pM. O pen circle - 
control; closed circle - 10 pM  L-frans-2,3-PDC; closed square - 30 pM  L- 
trans-2,3-PDC; closed triang le  - 100 pM  L-lrans-2,3-PDC (conducted in  
collaboration w ith  M.P. K avanaugh, Vollum Institute).
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Figure 4.4: C orrela tions B e tw een  S ynap tosom al Efflux R ates a n d  C u rren ts  
M easu red  in  Xenopus O ocy tes  E xpressing  EAAT1, EAAT2 a n d  EAAT3.
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Figure 4.4: C orrelations betw een inh ib ito r-induced  synaptosom al efflux 
rates and inh ib ito r-m edia ted  curren ts in oocytes w ere m ade using  Cricket 
G raph  III softw are (Islandia, NY). Efflux rates from  synaptosom es w ere  
quantified as described in C hapter 2 and  are repo rted  as a percentage of th e  
activity of L -glutam ate at 37°C. C urrents in  voltage clam ped X enopus  
oocytes expressing  EAAT1, EAAT2, and EAAT3 w ere m easured  as 
described in  C hap ter 2 and are reported  as a percentage of the cu rren t (Imax) 
induced by L-glutam ate. G raphs com paring synaptosom al efflux w ith  
currents observed a t EAAT1 an d  EAAT3 do n o t include d ihydrokainate , 
kainate, L-fnzns-2,3-PDC or cz's-5-Me-L-trans-2,3-PDC since there w as n o  
activity detected for these inh ib ito rs a t either of these transporter clones. 
The greatest correlation betw een  synaptosom al efflux rates and  Imax 
currents m easu red  in  the cloned transporters w as observed w ith  EAAT2 
w hich yielded an  r2 value of 0.612, com pared w ith  r2 = 0.043 and  r2 = 0.028 
for EAAT1 an d  EAAT3, respectively.
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Table 4.2: A nalogues w ere evaluated as inhibitors and  substrates in
oocytes expressing EAAT1, EAAT2, and EAAT3 as described in  Chapter 2. 
In  the instances w here com pounds exhibited no substrate activity (*), 
values w ere calculated by Schild analysis. In  the heteroexchange studies,
analogues w ere tested at concentrations = 10 X greater th an  the K; v a lu es
for inhibition of D-aspartate uptake as described in  C hapter 2. V alues 
indicating substra te  activity are reported as a percentage of the activity of L- 
glutam ate a t 37°C. The abbreviation n.d. denotes tha t no  activity was 
detected.
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Figure 4.5: M olecular m odeling  overlays u sing  a three p o in t fit o f th e
am ino group (purple), a-carboxylate carbon an d  distal carboxylate carbon
(red oxygens) o f a) substrates: L-glutam ate (green), L-£rans-2,4-PDC (red), 
czs-ACBD (w hite), and 2,4-MPDC (yellow); b) L -glu tam ate  an d  
nonsubstrates: L -glutam ate (green), L-antz-en<io-3,4-MPDC (blue), and  L- 
trans-2,3-PDC (orange); c) com posite  of the substrates an d  n onsubstra tes  
depicted in a) an d  b); d) the excess m olecular volum e of n onsubstra tes  vs. 
the m olecular v o lu m e  of substra tes as depicted by the yellow  grid. T his 
region represen ts the excess steric bu lk  associated w ith  th e  
nontransportab le  inhibitors th a t is believed to interact w ith  the tran sp o rt 
p ro tein  in  such  a  m anner as to reduce the transportab ility  of these  
com pounds. All m olecules are  m in im ized  conform ations (using SYBYL 
m olecular m odeling  softw are by Tripos). H ydrogens a re  om itted  for 
clarity.
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C hapter 5: N onsubstra te  Inh ib ito rs A ttenuate  the R eversal of G lu tam ate  
T ransporters in  Synaptosom es Follow ing a  M etabolic In su lt.
In tro d u c tio n
H igh-affinity, sod ium -dependent up take  systems are believed to play a
central role in  m ain ta in ing  glutam ate concentrations appropriate for
norm al synaptic  transm ission  and below  those th a t are excitotoxic.
Ironically, u n d e r some pathological conditions these sam e tran sp o rt
systems m ay actually participate  in the excitotoxic process by acting as sites
of efflux of L-glutam ate from  intracellular com partm ents (Takahashi et al.,
1997). N u m ero u s studies have  suggested that m etabolic insults w h ic h
com prom ise cellular energy levels can lead to the reversed  action of th e
transporter and  the m ovem en t of L-glutam ate dow n its concen tra tion
gradient in to  the  extracellular space (K auppinen e t al., 1988; Sanchez-
Prieto and  G onzalez, 1988; Gem ba et al., 1994; Szatkow ski and A ttw ell,
1994; L onguem are and Sw anson, 1995). This pathw ay, possibly in
com bination w ith  a lternative routes of L-glutam ate efflux (Kimelberg et
al., 1990), cou ld  contribute to the rise in  extracellular glutam ate levels
observed in  m odels of anoxia and ischem ia (Benveniste et al., 1984;
Roettiger an d  Lip ton, 1996).
In th is chap ter we exam ined the efflux of [3H]-D-aspartate, a selective
substrate of the  high-affinity, sod ium -dependen t g lu tam ate carriers, fro m
65
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synaptosom es in  response to a m etabolic insu lt (i.e., po tassium  cyanide 
and  iodoacetate). We dem onstrated  th a t the metabolic in su lt-m ed ia ted  
efflux of [3H]-D-aspartate from  the synaptosom es exhibited a tim ecou rse  
sim ilar to the heteroexchange-m ediated efflux that was observed in  
Chapter 4. In  addition, like the efflux of rad io ligand that was induced b y  L- 
glutam ate, the metabolic inhibitor-induced efflux could be attenuated  w ith  
nontransportable uptake inhibitors, e.g. L-trans-2,3-PDC a n d  
dihydrokainate. These results thus add fu rther strength to the m odel of 
injury-induced efflux th rough  the g lu tam ate carriers and identify a n o v e l  
strategy w ith  w hich to attenuate this process.
Results and  D iscussion
Similar to w h a t was observed w hen synaptosom es containing pH]-D- 
aspartate w ere exposed to 10 pM  L-glutam ate (Chapter 4), a stim ula tion  of 
the efflux of pre-accum ulated amino acid w as also observed w h e n  
synaptosom es w ere exposed to a chem ical in su lt consisting of p o tass iu m  
cyanide (KCN, 5 mM) and iodoacetate (IOA, 1 mM) (Figure 5.1). T h e  
com bination of an  electron transport chain blocker (KCN) and a glycolytic 
inhibitor (IOA) has been em ployed in  n u m ero u s studies as a m etabolic  
insu lt and as a sim plified chem ical m odel of ischem ia/anoxia because of 
its ability to inh ib it respiration, deplete ATP levels, and erode m em b ran e  
potentials (K auppinen e t al., 1988; Reiner e t al., 1990; Zeevalk and N icklas,
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1991; L onguem are an d  Sw anson, 1995). As illustrated in  Figure 5.1A, th e  
efflux of [3H ]-D-aspartate p roduced by KCN and IOA exhibited a tim e  
course v e ry  sim ilar to th a t of g lu tam ate-m ediated  heteroexchange. O ver a 
5 m in  p e rio d  the synaptosom al con ten t of [3H]-D-aspartate w as reduced  to 
about 50% of its o rig inal level. In terestingly , an  analogous increase in  
efflux w as n o t observed w hen  synaptosom es containing [3H]-GABA w ere 
exposed to these sam e m etabolic inh ib ito rs (Figure 5.1B). W h eth er th is  
lack of response  w as attributable to: x) the  m etabolism  or sequestra tion  of 
GABA in  synaptic vesicles (unlikely, given the extent o f th e  
hom oexchange-m ediated  efflux), ii) the GABA pool being less sensitive  to 
m etabolic insult, as suggested by (H au p tm an  et al., 1984), or iii) as a 
consequence of the inhib itor-induced efflux of [3H]-GABA being m asked  by  
a larger basal rate of efflux (Figure 5.1B), rem ains to be determ ined. W h ile  
the p o ten tia l action of KCN and  IOA at alternative sites can n o t be 
excluded, these results are consistent w ith  p revious dem onstra tions th a t 
the chem ical inh ib ition  of cellular resp ira tion  increases ex tracellu lar 
levels o f L-glutam ate in  a v arie ty  o f physiological p rep a ra tio n s 
(K auppinen  et al., 1988; Sanchez-Prieto and  Gonzalez, 1988; Z eevalk  and  
Nicklas, 1991; M adl an d  Burgesser, 1993; Gem ba e t al., 1994).
In  ad d itio n  to an  ability to block heteroexchange, the n o n tran sp o rtab le  
inhibitors L-frans-2,3-PDC and  d ihydrokainate  also attenuated the efflux of 
[3H ]-D -aspartate tha t w as induced b y  the  m etabolic inhibitors. This f in d in g  
suggests th a t the  sam e transport system  is invo lved  in  bo th  the  processes
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of heteroexchange an d  transporter reversal d u rin g  metabolic insult (Table 
5.1, Figure 5.1A). In  contrast to the ability  o f an  analogue to block 
g lu tam ate-m ediated  heteroexchange by directly com peting w ith  
extracellular L -glutam ate for the carrier b in d in g  sites, the results lead  to 
the conclusion th a t the occupation of ex ternal binding sites by a 
nontranslocatable analogue reduces the ra te  a t w hich  an  in ternal substrate 
can egress th ro u g h  this system . M echanistically, this process is also 
distinct from  the reduction  in  the  m etabolic inhib ito r-induced  efflux of 
[3H]-D-aspartate from  cultured astrocytes th a t w as produced in tracellu larly  
by pre-equilibrating the  cells w ith  com petitive  inhibitors tha t were also 
substrates (D,L-j3-THA and L-frans-2,4-PDC) (Longuem are and  Sw anson,
1995). It therefore appears that the b ind ing  of a nontransportab le  analogue 
m ay essentially trap  the  carrier b inding  site on  the extracellular face of the  
plasm a m em brane. In  support of this in te rp re ta tion , a  reduction in  the  
metabolic inh ib ito r-induced  efflux w as observed only w ith the  
nontransportab le  blockers" and  no t w ith  substra te  inhibitors {e.g., L-anti- 
endo-3,4-MPDC, 2,4-MPDC, D,L-p-THA and  L-trans-2,4-PDC) (Table 5.1). In  
fact, w hen  2,4-MPDC w as included in the  assay w ith  KCN and IOA, the  
resulting efflux of am ino acid w as significantly h igher than tha t produced 
by KCN and  IOA alone. Thus, po ten t substrates can even exacerbate the  
transporter reversal caused by a m etabolic insult. It is also acknow ledged 
that the a tten u a tio n  of the [3H]-D-aspartate efflux by L-frans-2,3-PDC was 
no t com plete (e.g., abou t 50% a t 5 m in, F igure 5.1A), suggesting th a t a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
69
portion  of the in su lt-induced  efflux m ay also have  been occurring v ia  
either an  EAAT subtype insensitive to L-frans-2,3-PDC (see below) or 
through a non-EAAT m ediated  m echanism  (Kim elberg e t al., 1990).
Interestingly, bo th  d ihydrokainate (Pines et al., 1992; A rriza  et al., 1994; 
Vandenberg, 1998) an d  L-frans-2,3-PDC (see C hapter 4) appear to be 
selective inhibitors of the EAAT2/GLT-1 transporter sub type  believed to be 
localized prim arily  on  glia in  the CNS (for review  see: G egelashvili an d  
Schousboe, 1998). The specificity of these analogues w ould , in  tu rn , 
suggest tha t a t least som e portion  of the observed efflux of [3H]-D-aspartate 
originated from  glial elem ents w ith in  the synaptosom al p reparation  (see: 
Chapter 4, Heim  e t al., 1976; N akam ura et al., 1993). It is also w o rth  no ting  
that the inclusion  of L-flnfz-endo-3,4-MPDC, a po ten t non transportab le  
inhibitor of EAAT2 and  substrate of EAAT1 and  EAAT3 (Chapter 4), did 
no t attenuate the m etabolic insult-induced efflux. The po ten tia l for th is 
analogue to inh ib it the observed efflux at EAAT2 m ay have been 
counteracted by its ability to act as a substrate, and  th u s participate in  
heteroexchange, a t EAAT1 and  EAAT3. The presence of glial transporters 
in  this subcellular fraction is also consistent w ith  the  dem onstra tion  th a t 
synaptosom es p repared  from  mice deficient in  GLT-1 exhibited a m arked  
loss in the ability to tran spo rt L-glutamate (Tanaka e t al., 1997), as was 
discussed in  C hapter 4. W hile m ore selective inh ib ito rs and  additional 
kinetic studies w ill be needed to quantitatively delineate  the  specific 
cellular pools and  ind iv idua l proteins that contribute to excitatory am ino
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a d d  efflux d u rin g  m etabolic insult, these findings h igh ligh t the use of 
nontransportab le  uptake inhibitors as a novel strategy to regulate  th is 
process.
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Figure 5.1: Synaptosom al efflux of A) [3H]-D-aspartate, o r  B) [3H]-GABA, 
reported  as a percentage of initial radiolabel con ten t (1552±65 pm ol pH]-D- 
a sp a rta te /m g  pro tein  and 3887±263 pm ol [3H ]-G A B A /m g protein), was 
follow ed over a period of 5 m in  in the presence a n d  absence of the  
indicated  com pounds. Synaptosom es m ain tained  a t 4°C d id  n o t exhibit a 
significant loss of [3H]-substrate, while the inclusion  o f L-glutam ate or 
GABA a t 37°C caused an  efflux of over 50% of synap to som al pHj-D- 
aspartate  o r [3H]-GABA, respectively. A  m etabolic in su lt o f 5 m M  KCN 
and Im M  IOA (iodoacetate) caused an efflux of [3H ]-D -aspartate sim ilar in  
extent to th a t caused by 10 pM  L-glutam ate. In  contrast, 5 m M  KCN and 
Im M  IOA caused only a slight, albeit statistically nonsign ifican t, increase 
in  the efflux of [3H]-GABA. Interestingly, inclusion  of the n o n ­
transportab le  up take  inhibitor L-frans-2,3-PDC significantly  a ttenuated  the  
efflux of [3H]-D-aspartate that w as caused by the m etabolic insu lt. V alues 
are repo rted  as m ean ± S.E.M. from  at least 4 duplicate de te rm ina tions. 
Statistical com parisons w ere m ade using  an  A lternate  W elch t-test 
(G raphPad, San Diego, CA) th a t does no t assum e equal SD's: * pc.0001 
versus C ontro l efflux; t  p<.005 versus KCN- and  IO A -induced efflux.
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Table 5.1: A ttenuation of KCN- and IOA-Induced Efflux of 
[3H]-D-Aspartate from  Synaptosom es by N ontransportable Inhibitors.
C om pounds [3H]-D-Aspartate Efflux 
(% of Control)
C ontro l 100 ± 4
10 pM  L-G lutam ate 233 ± 10 a
5 mM  KCN & 1 mM  IOA 224 ± 18 a
5 mM KCN & 1 m M  IOA & 
300 pM  L-fr£ms-2,3-PDC
117 ± 12 b
5 mM KCN & 1 m M  IOA & 
300 pM  DHK
121 ± 17 b
5 mM KCN & 1 m M  IOA & 
50 pM  L-a«fi-endo-3,4-MPDC
220 ± 18 a
5 mM KCN & 1 m M  IOA & 
75 pM  2,4-MPDC
305 ± 30 a
5 m M  KCN & 1 m M  IOA & 
20 pM  D,L-p-THA
280 ± 4 2 a
5 mM KCN & 1 m M  IOA & 
15 pM  L-frans-2,4-PDC
284 ± 32 a
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Table 5.1: Efflux o f synaptosom al [3H]-D-aspartate w as quantified  over a 2 
m in period  a t 37°C and  is reported as percent of C ontro l {i.e., efflux in the 
absence of added  substrates). Initial content of the synaptosom es was 
1552±62 pm ol [3H]-D-aspartate, and C ontrol rate of efflux was 114±4 
p m o l/m in /m g  p ro te in  [3H]-D-aspartate. The efflux of [3H]-D-aspartate 
induced by a m etabolic insult of 5 m M  KCN and  1 m M  IOA was 
significantly a ttenuated  by the nontransportable  up take  inhib itors L-trans-
2,3-PDC and  dihydrokainate, but no t by the transportab le  inh ib ito rs L-anti- 
endo-3,4-MPDC, 2,4-MPDC, D,L-p-THA and L-frans-2,4-PDC. Values are 
reported as m ean  ± S.E.M., n= 4-57 duplicate de term inations. Statistical 
com parisons w ere m ade using an A lternate W elch t-test (G raphPad, San 
Diego, CA): a, p<0.0001 versus C ontrol efflux, b, p<0.0005 versus KCN 
and IOA induced efflux.
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C hap ter 6: S um m ary  a n d  C onclusions
Thirty  years ago, few  w ould  have accepted the a -am in o  a d d  L- 
g lutam ate as a n eu ro tran sm itte r , and  m uch less as the p rim ary  exd ta to ry  
transm itte r a t all synaptic  sites w ith in  the m am m alian  cen tral n e rv o u s  
system. Since this tim e, selective ligands have  been used  to de linea te  
ind iv idua l subtypes of receptors, g lu tam atergic pathw ays have b een  
m apped  in  the b rain , an d  a separate transport system  w as identified  th a t  
term inates the actions of the  transm itter in the  synaptic d e ft. W ith th e  
explosion in the  field  of m olecular biology w ith in  the last te n  years, th e  
study of the pharm acology , physiology and  structu ra l analysis of th e  
glutam ate receptors a n d  transporters has been taken  to new  heights. W e ll 
over a dozen  in d iv id u a l subunits have been cloned for the  th ree  fam ilies 
of ionotropic receptors, and  a t least six subtypes o f m etabotropic receptors 
have been identified  (for review  see: Cotm an et al., 1995; D ingledine et al., 
1999). Pharm acological developm ents have n o t been far beh ind  w ith  
several h u n d red  agonists and antagonists developed, m any w ith  
selectivity for in d iv id u a l subtypes of EAA receptors. The year 1992 
b rought the  in itial c lon ing  of three high-affinity g lutam ate transporte rs , 
GLAST, GLT-1, and  EAAC1 from  anim al tissue (Kanai and  Hediger, 1992; 
Pines et al., 1992; Storck et al., 1992), and  the isolation of th ree  coun terparts  
from  h u m a n  tissue, EAAT1, EAAT2, and EAAT3, respectively, fo llow ed
75
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shortly thereafter (Arriza e t al., 1994). To date, five h u m an  subtypes h a v e  
been identified, m ost recently  EAAT4 an d  EAAT5 (Fairm an et al., 1995; 
A rriza et al., 1997). The pharm acology of these transporters, how ever, h as  
rem ained in  a relative state of infancy as com pared w ith  th a t of the  EAA 
receptors.
Bearing this in  m ind , the  first p o rtio n  of this w ork  was directed  
tow ards the  identification  of po ten t inhibitors of the  h igh-affin ity  
glutam ate transporters p resen t in forebrain  synaptosom es. It w as 
previously  dem onstra ted  th a t the incorpora tion  of L-glutam ate o r L- 
aspartate in to  a constrained  ring  system  could produce po ten t an d  
selective inhib ito rs (Bridges e t al., 1991; Bridges et al., 1993). This strategy 
w as used in  the p resen t s tu d y  to identify  th ree  novel types of in h ib ito rs  
based  on the pyrro lid ine ring  structure: 2,3-pyrrolidine dicarboxylates, 3,4- 
m ethanopyrro lid ine  dicarboxylates and  2 ,4 -m ethanopyrro lid ine  
dicarboxylate (Bridges et al., 1994; Willis e t al., 1996; Esslinger et al., 1998).
• L-frans-2,3-PDC w as fo u n d  to be a m oderate ly  po ten t, com petitive  
in h ib ito r of h igh-affin ity , synap tosom al u p tak e  of L-glutam ate. Of th e
series of 2,3-pyrrolidine dicarboxylates th a t w as prepared and  tested, L- 
frans-2,3-PDC w as found to be  the  only isom er w ith  activity for in h ib itin g  
the  uptake of [3H]-D-aspartate into synaptosom es. This constra ined  
analogue of L-aspartate acted w ith  a sim ilar potency as the  well k n o w n  
up take  inhibitor d ihydrokainate .
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• L-anti-endo-3,4-M PDC w as dem onstra ted  to be  a potent, com petitive  
in h ib ito r of the synaptosom al g lu tam ate  up take  system . Of the th ree  
bicyclic diastereom ers of L-3,4-m ethanopyrrolidine dicarboxylate that w ere 
evaluated  for the  ability to inh ib it the high-affinity synaptosom al 
g lutam ate transporter, only L-anh'-endo-3,4-MPDC was found  to show  
activity. This isom er relied on th e  addition  of a 3,4-m ethano bridge to the  
pyrrolid ine ring in  o rder to m im ic the folded conform ation  of L-frans-2,4- 
PDC. L-anti-endo-3,4^MPDC  inh ib ited  the uptake of [3H]-D-aspartate to a 
sim ilar extent as the endogenous substra te  L-glutam ate.
• 2 ,4-m ethanopyrro lid ine dicarboxylate (2,4-MPDC) was found  to be a 
potent, com petitive  inh ib ito r of the  synaptosom al transport of L- 
g lu tam ate . By ad d in g  further conform ational constrain t to the pyrro lid ine  
ring via the incorporation of a m ethano  bridge, th is bicyclic analogue of L- 
glutam ate was designed to m im ic the extended conform ation of L-frans-
2,4-PDC. 2,4-MPDC inhibited synaptosom al g lutam ate transport w ith  
sim ilar potency  as L-glutam ate an d  L-anfz-enrfo-3,4-MPDC.
• M olecular m odeling  studies w ere  perform ed to com pare the  proposed 
b ind ing  conform ations of L-trans-2,3-PDC, L-anfi-endo-3,4-MPDC and  2,4- 
M PDC w ith  those o f L-glutam ate a n d  L-£ra«s-2,4-PDC. Using a three p o in t
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fit of the am ino group, a-carboxylate carbon and distal carboxylate carbon, 
a high degree of overlap w as found for the functional g roup  positionings 
of the five m en tioned  inhibitors. The results suggest th a t while the  
arrangem ents of the functional groups are im portan t for transporter 
binding, im p o rtan t considerations can also be m ade regarding th e  
stereoselectivity of the b ind ing  site and the  tolerance for add itional steric 
volum e occupied by  the backbones of the constrained inhibitors.
W hile n u m ero u s studies in  the past have used analogues of L- 
glutam ate to p robe the functions of the EAA transporters (for review  see: 
Bridges et al., 1999), very  few  have a ttem pted  to d istingu ish  these 
analogues on  the  basis of substrates and nonsubstrates. In  o ther words, it  
was presum ed th a t inhibitors of glutam ate uptake could be differentiated 
betw een m olecules that com pete w ith L-glutam ate for the b in d in g  site and  
are then transported  them selves (substrate inhibitors), an d  inhibitors th a t 
com pete for b ind ing  b u t are n o t translocated (nontransportable inhibitors). 
By utilizing the  process of heteroexchange, a  m ethod w as developed for 
rapidly delineating  substrates from nonsubstra te  inh ib ito rs of the  
synaptosom al transporters. Thus, follow ing the initial identification of 
the inhibitory properties of a series of analogues, additional investigations 
into the m echanism  of substrate  specificity of glutam ate transport w ere
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conducted using  these m olecules (C ham berlin  e t al., 1998; Esslinger et al., 
1998; Koch et al., 1999).
• The process o f transporter-m ed ia ted  heteroexchange w as exploited in  
synaptosom es in  order to rapid ly  d is tin g u ish  transportab le  from  
n on transportab le  inh ib ito rs. It w as d em o n stra ted  that the  endogenous 
substrate L -glutam ate could cause the efflux of radiolabeled D-aspartate 
tha t had been prev iously  sequestered in to  the synaptosom es. T he 
observed efflux appears to represen t the tran sp o rte r m ediated-exchange of 
in ternal for ex ternal substrate. These find ings w ere su p p o rted  by th e  
observations th a t the  transporter-specific substra tes L -glutam ate and L- 
aspartate could stim ulate  exchange w hile GABA, NM DA, kainate and  
AM PA could not.
• A w ide range of substrate activities w as fo u n d  w ith in  th e  library of 
conform ationally  constra ined  inh ib ito rs. A  n u m b er of p o ten t inh ib ito rs 
w ere identified th a t shared  sim ilar positionings of their functional groups 
yet exhibited m arked ly  different capacities to serve as substrates for the  
high-affinity g lu tam ate  tran sp o rt system. In  addition, the  substrate 
activities did n o t necessarily correlate w ith  the  ability  of the com pounds to 
b ind  to the transporte r. It w as dem onstra ted  th a t 2,4-MPDC, L-anti-endo-
3,4-MPDC, L-frarts-2,4-PDC, c/s-ACBD and  D,L-(i-THA act as substrates for
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the synaptosom al g lu tam ate uptake system . In  contrast, L-frans-2,3-PDC, 
czs-5-Me-L-fnms-2,3-PDC and  dihydrokainate proved to be com petitive  
inhibitors of up take th a t d id  no t exhibit activity as substrates.
• M olecular m odeling  com parisons w ere u sed  to refine  the  
pharm acophore m odel o f the  substrate  b in d in g  site on  the  tran sp o rte r and  
to explore the  chem ical properties tha t define the substra te  activ ities of 
inhib itors. It was found  w ith in  the  library of analogues th a t 
conform ational restric tion  does not necessarily dictate substrate activity. 
Regions of excess steric vo lum e associated w ith  the carbon backbones of 
the nonsubstrates w ere identified that w ere distinct rela tive  to the space 
occupied by  the backbones of the substrates. It is likely th a t steric excess in  
these specific positions represents a determ in ing  factor as to w he ther o r 
no t the analogue can be transported. W hile sim ilar positionings of the  
functional g roups m ay allow  binding to occur, it can be concluded th a t the  
excess vo lum e occupied by the backbones of the n o n tran sp o rtab le  
analogues m ay in teract in  an  unfavorable m anner w ith  specific d o m ain s  
on  the transporter p ro te in  th a t govern translocation.
• The pharm acological p ro file  of the synaptosom al p repara tion  exhibited  
the greatest correspondence w ith  EAAT2, a  transporter su b ty p e  believed  to 
be prim arily  of glial orig in . Electrophysiological characterization  of
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transport into X enopus  oocytes expressing the h u m an  transporter clones 
provided an  a lternative approach  w ith  w hich  to corroborate th e  
conclusions derived  from the  heteroexchange studies. W hen the sam e 
library of analogues was characterized electrophysiologically a t EAAT1, 
EAAT2, and EAAT3, it w as found  tha t the pharm acological profile of 
substrate and nonsubstra te  inhib itors of the  synaptosom al system  
exhibited the greatest sim ilarity w ith  the EAAT2 subtype. This conclusion  
is quite in teresting  as EAAT2 is though t to be expressed prim arily  in  
astrocytes.
N um erous stud ies have dem onstra ted  that m etabolic insults, such as 
anoxia and ischem ia, which com prom ise cellular energy levels can lead to 
the reversed action of the high-affinity  g lutam ate transporters and  the  
m ovem ent of L-glutam ate dow n  its concentration gradient into th e  
extracellular space (K auppinen et al., 1988; Sanchez-Prieto and  G onzalez, 
1988; Gemba et al., 1994; Szatkow ski and A ttwell, 1994; Longuem are and  
Swanson, 1995). E levated levels of extracellular L-glutam ate can in  tu rn  
result in the overactivation  of EAA receptors an d  thus induce excitotoxic 
neuronal injury (Choi, 1994; R othm an and O lney, 1995). In the final 
chapter of the study, it w as dem onstrated th a t a metabolic in su lt 
(potassium  cyanide and  iodoacetate) designed to m im ic conditions d u rin g  
ischemia and anoxia, could be used  to induce the efflux of am ino acid v ia  
the high-affinity glutam ate transporters. In addition, selective up take
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inhibitors w ere used  in an  a ttem p t to a ttenuate the tran sp o rte r  reversa l 
(Koch e t al., 1999).
• A chem ically-induced  m etabolic  in su lt causes the  rev e rsa l of h igh- 
affinity  g lu tam ate transporters in  synaptosom es. Synap tosom es 
contain ing  radiolabeled D -aspartate were exposed to a m etabolic  in su lt 
consisting of an electron tran sp o rt chain  blocker (potassium  cyanide) an d  a 
glycolytic inh ib ito r (iodoacetate). The resulting efflux of am in o  acid was 
sim ilar in  extent to tha t w hich  w as observed d u rin g  g lu tam ate-m ed ia ted  
heteroexchange.
• N on transpo rtab le  inh ib ito rs  can  be used to a ttenuate  th e  m etabolic 
inh ib ito r-induced  efflux of am ino  a d d  from  synaptosom es. T he substrate
inhibitors L-anti-endo-3,4-MPDC, 2,4-MPDC, D,L-P-THA a n d  L-fnms-2,4-
PDC h ad  either no effect or in  fact exacerbated the  m etabolic in h ib ito r- 
induced efflux, as w as the case for 2,4-MPDC. O n the o th e r  h an d , the  
non transportab le  inhibitors L-frans-2,3-PDC and  d ihydrokainate , w h ich  
share a sim ilar ability to block heteroexchange, a ttenuated  th e  efflux of D- 
aspartate observed during  the m etabolic insult. These resu lts lead to th e  
condusion  th a t the  occupation of extracellular transporter b in d in g  sites by 
nonsubstrate  analogues reduces the  rate  a t w hich an  in tracellu lar substrate 
can egress th rough  this system . In  addition, these findings ad d  fu r th e r
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streng th  to the m odel of glutam ate transporter reversal d u ring  a m etabolic 
insult and  identify  a novel strategy w ith w hich to attenuate this process.
The w ork  deta iled  in  this s tudy  w ill no doub t contribute to the  fu rther 
characterization a n d  u nders tand ing  of the im portan t physiological roles of 
the h igh-affin ity  g lu tam ate  transporters in  the m am m alian  central 
nervous system . From  a m edical science perspective, progress in this 
direction is critical in  lieu of the  vast num ber of pathologies in  w hich L- 
glutam ate appears to be involved . The need is apparent, how ever, for a 
greater num ber of m ore highly selective inhibitors of the glutam ate 
transporters. M ore deta iled  m olecular m odeling studies as w ell as fu rther 
m odifications to th e  pyrro lid ine  dicarboxylate them e will undoubted ly  
provide an even  greater array  of analogues w ith  w hich to probe the 
pharm acophores of the ind iv idua l transporter subtypes. Selective 
substrates and  non transpo rtab le  inhibitors of the EAATs w ill be 
particularly  usefu l in  e lucidating  the con tribu tion  of the in d iv id u a l 
subtypes to n o rm al signaling  processes as w ell as their invo lvem en t in  
pathological scenarios. The developm ent of m ore po ten t and  selective 
nontransportab le  inh ib ito rs m ay also provide a novel therapeutic  avenue  
for the trea tm en t of conditions such  as stroke and traum a in  w hich  
transporter reversa l and  excitotoxic levels of L-glutam ate m ay be a 
concern.
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